ClinicalTrials.gg
CompletedNCT01942668REPLENISHUpdated May 6, 2019Results posted

A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms

A Phase 3 interventional study of Estradiol and Progesterone in Menopause, sponsored by TherapeuticsMD. Completed at 119 sites in United States. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-05-06.

Sponsored by TherapeuticsMD · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,845
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing estradiol in Hot Flashes — none open to participants now, none under way, none of them phase 3. Estradiol · Hot Flashes.

Enrollment
2nd of 13
1,845 · median 431
Started
2013
the only one that year
Phase 3
8 of 13
none open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
TherapeuticsMD

Among the 13 studies testing estradiol in Hot Flashes, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 8 in phase 3, and was the 13th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing estradiol in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About estradiol

Estradiol: first FDA approval 1954 (DELESTROGEN), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing estradiol in Hot Flashes as a file.
02

Study summary

This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.

Read the detailed description

Postmenopausal subjects with an intact uterus who meet the study entry criteria will be randomized to one of five treatment arms (four active and one placebo) and followed for 12 months. During the Screening period all subjects will be provided with a diary to self-assess the frequency and severity of their vasomotor symptoms. Subjects experiencing a minimum daily frequency of ≥7 (or ≥50 per week) moderate to severe hot flushes will participate in a VMS Substudy during the first 12 weeks of treatment. The Substudy subjects will be stratified by treatment arm within the sites, and only Substudy subjects have the possibility of being randomized to placebo. Subjects who qualify for the study except for experiencing a minimum daily frequency of ≥7 (or ≥50 per week) moderate to severe hot flushes will be stratified within sites to one of the four active treatment arms and followed for 12 months, but will not participate in the VMS Substudy. (However, VMS information will be collected from all subjects during the first 12 weeks of treatment.) All Study Subjects: Postmenopausal women with an intact uterus who seek relief from hot flushes and meet all other inclusion/exclusion criteria are eligible for 12 months of study treatment.

VMS Substudy Subjects: A subset of All Study Subjects who have ≥7 per day or ≥50 per week moderate to severe hot flushes (as determined during Screening) are eligible for the 12-week VMS Substudy and for a total of 12 months of study treatment.

Clinical evaluations will be performed at the following time points:

  • Screening Period (Week: - 8.5) (up to -60 Days)
  • Visit 1 Randomization (Week 0) (Day 1)
  • Visit 2 Interim (Week 4)
  • Visit 3 Interim (Week 8)
  • Visit 4 Interim (Week 12)
  • Visit 5 Interim (Month 6)
  • Visit 6 Interim (Month 9)
  • Visit 7 End of Treatment (Month 12)
03

Conditions studied

  • Menopause

Browse trials for

Keywords

  • Vasomotor symptoms
  • Hot flashes
  • Endometrial protection
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be a female between the ages of 40 and 65 years (at the time of randomization) who is willing to participate in the study, as documented by signing the form.
  2. Be a woman with an intact uterus and a Screening serum estradiol level of ≤50 pg/mL. Postmenopausal is defined herein as:

    1. ≥ 12 months of spontaneous amenorrhea, or
    2. at least 6 months of spontaneous amenorrhea with a Screening serum FSH level of >40 mIU/ml, or
    3. ≥ 6 weeks postsurgical bilateral oophorectomy.
  3. Be seeking treatment or relief for vasomotor symptoms associated with menopause.
  4. To participate in the VMS Substudy, a subject must also report ≥7 moderate to severe hot flushes per day, or ≥50 per week, at the baseline assessment during Screening (subjects whose hot flushes are less frequent may still participate as non-Substudy subjects.

    Note: A minimum of 14 consecutive days of complete hot flush diary data are required during the baseline assessment at Screening, and these consecutive days must occur within the last 14 days prior to the Randomization visit (not counting the Randomization visit day itself). The most recent 7 consecutive days of data prior to randomization (Day -7 to Day -1) will be used to determine the baseline number of mild, moderate and severe hot flushes for each subject.

  5. Have a (BMI) less than or equal to 34 kg/mP2P. (BMI values should be rounded to the nearest integer [e.g., 34.4 rounds down to 34, while 26.5 rounds up to 27]).
  6. Be willing to abstain from using products (other than study medication) that contain estrogen, progestin, or progesterone throughout study participation.
  7. Be judged by the principal or sub-investigator physician as being in otherwise generally good health based on a medical evaluation performed during the Screening period prior to the initial dose of study medication. The medical evaluation findings must include:

    1. a normal or non- physical examination, including vital signs (sitting blood pressure, heart rate, respiratory rate and temperature). Sitting systolic blood pressure is ≤140 mmHg and diastolic blood pressure ≤90 mmHg at Screening. A subject may be taking up to two antihypertensive medications.
    2. a normal or non-clinically significant pelvic examination.
    3. a mammogram that shows no sign of significant disease (can be performed within previous 6 months prior to initial dose of study medication). Subjects must have a BI-RADS 1 or 2 to enroll in the study. An incomplete mammogram result, i.e. BI-RADS 0, is not acceptable. The site must obtain a copy of the official report for the subject's study file, and it must be verified that the mammogram itself is available if needed for additional assessment.
    4. a normal or non-clinically significant clinical breast examination. An acceptable breast examination is defined as no masses or other findings identified that are suspicious of .
    5. a normal Screening Papanicolaou ("Pap") smear. (Subjects with findings of atypical glandular cells [AGC], AGUS, ASCUS with high risk HPV type upon reflex testing, LSIL, ASC-H, HSIL, dysplastic cells, or malignant cells must be excluded from randomization.)
    6. an acceptable result from an evaluable Screening endometrial . The endometrial biopsy reports by the two central pathologists at Screening must each specify one of the following: proliferative endometrium; weakly proliferative endometrium; disordered proliferative pattern; secretory endometrium; endometrial tissue other (including benign, inactive or atrophic fragments of endometrial epithelium, glands, stroma, etc); endometrial tissue insufficient for diagnosis; no endometrium identified; or no tissue identified. However, at least one pathologist must identify sufficient tissue to evaluate the biopsy. Additionally, the endometrial biopsy reports by the two central pathologists of Other Findings at Screening must each specify one of the following: endometrial polyp not present; benign endometrial polyp; or polyp other. (See Exclusion criterion #27)
    7. a normal or non-clinically significant 12-lead .

Exclusion criteria

Exclusion Criteria:

  • To participate in the study, a subject must NOT:

    1. Be currently hospitalized.
    2. Have a history of thrombosis of deep veins or arteries or a thromboembolic disorder.
    3. Have a history of coronary artery or cerebrovascular disease (e.g., myocardial infarction, angina, stroke, ).
    4. Have a history of a chronic liver or kidney dysfunction/disorder (e.g., or chronic renal failure).
    5. Have a history of a malabsorption disorder (e.g., gastric bypass, Crohn's disease).
    6. Have a history of gallbladder dysfunction/disorders (e.g., cholangitis, cholecystitis), unless gallbladder has been removed.
    7. Have a history of diabetes, thyroid disease or any other endocrinological disease. (Subjects with diet-controlled diabetes or controlled hypothyroid disease at Screening are not excluded.)
    8. Have a history of estrogen-dependent neoplasia.
    9. Have a history of atypical ductal hyperplasia of the breast.
    10. Have a finding of uterine fibroids at Screening.
    11. Have had a uterine ablation.
    12. Have a history of undiagnosed vaginal bleeding.
    13. Have any history of endometrial hyperplasia, melanoma, or uterine/endometrial, breast or ovarian cancer.
    14. Have any history of other within the last 5 years, with the exception of basal cell (excluded if within 1 year) or non-invasive squamous cell (excluded if within 1 year) carcinoma of the skin.
    15. Have a history of any other cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological (e.g., bipolar disorder, schizophrenia, major depressive disorder), or musculoskeletal disease or disorder that is clinically significant in the opinion of the Principal Investigator or Medical Sub-Investigator.
    16. Have any of the following clinical laboratory values at Screening:

      1. fasting triglyceride of ≥300 mg/dL and/or total cholesterol of ≥300mg/dL
      2. positive laboratory finding for Factor V Leiden mutation
      3. or ALT ≥1.5 times the (ULN)
      4. fasting glucose >125 mg/dL
    17. Be known to be pregnant or have a positive urine pregnancy test. (Note: A pregnancy test is not required for subjects who have had bilateral tubal ligation, bilateral oophorectomy, or are 55 years old or greater and have experienced cessation of menses for at least 1 year.)
    18. Have to estrogen and/or progestin therapy or allergy to the use of estradiol and/or progesterone or any components of the drugs.
    19. Use 15 or more cigarettes per day or currently use any electronic cigarettes.
    20. Have a history of drug and/or alcohol abuse within one year of start of study.
    21. Have used, within 28 days prior to the initial dose of study medication at Visit 1, any medication known to induce or inhibit enzyme activity that may affect estrogen and/or progestin drug metabolism. (See 48TUSection 4.3U48T)
    22. Have used, within 28 days prior to Screening, or plan to use during the study, any prescription or over-the-counter (OTC) medications (including herbal products, such as St. John's Wort) that would be expected to alter progesterone or estrogen activity or is being used to treat vasomotor symptoms. (See Section 4.3U48T)
    23. Have used estrogen alone or estrogen/progestin, SERM (selective estrogen receptor modulator), testosterone, or estrogen/testosterone for any of the following time periods:

      1. Vaginal nonsystemic hormonal products (rings, creams, gels) within 7 days prior to Screening, or vaginal systemic products (e.g., FemRing) within 28 days prior to Screening.
      2. Transdermal estrogen alone or estrogen/progestin products within 8 weeks prior to Screening.
      3. Oral estrogen and/or progestin and/or SERM therapy within 8 weeks prior to Screening.
      4. Progestational implants, estrogen or estrogen/progestational injectable drug therapy within 3 months prior to Screening.
      5. Estrogen pellet therapy or progestational injectable drug therapy within 6 months prior to Screening.
      6. Percutaneous estrogen lotions/gels within 8 weeks prior to Screening.
      7. Oral, topical, vaginal, patch, implantable or injectable androgen therapy within 8 weeks prior to Screening.
    24. Have used an intrauterine device (IUD) within the 12 weeks prior to Screening.
    25. For subjects in the VMS Substudy only: use of medication that may affect the outcome of the vasomotor symptom endpoints within 28 days prior to Screening (e.g. SSRIs [selective serotonin reuptake inhibitors], SNRIs [serotonin and norepinephrine reuptake inhibitors], aldomet, dopaminergic or antidopaminergic drugs, gabapentin, clonidine, or bellergal.)
    26. Have any reason which, in the opinion of the Principal Investigator or Medical Sub-Investigator, would prevent the subject from safely participating in the study or complying with protocol requirements.
    27. Have a Screening endometrial sample that is found by both primary pathologists to have endometrial tissue insufficient for diagnosis, no endometrium identified, or no tissue identified. (With the approval of the Medical Monitor, the Screening endometrial biopsy may be repeated once.)
    28. Endometrial polyps with atypical nuclei reported by at least 1 central pathologist.
    29. Have contraindication to any planned study assessments (e.g., endometrial biopsy).
    30. Have participated in another clinical trial within 30 days prior to Screening, have received an investigational drug within the three months prior to the initial dose of study medication, or be likely to participate in a clinical trial or receive another investigational medication during the study.
    31. Currently use marijuana.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
1,845 participants (actual)

Study arms

  • Experimental
    Treatment 1

    Combined Estradiol 1 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.

    Drug: Estradiol · Drug: Progesterone · Drug: Placebo

  • Experimental
    Treatment 2

    Combined Estradiol 0.5 mg / Progesterone 100 mg softgel capsule formulation and placebo taken orally once a day for twelve months.

    Drug: Estradiol · Drug: Progesterone · Drug: Placebo

  • Experimental
    Treatment 3

    Combined Estradiol 0.5 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.

    Drug: Estradiol · Drug: Progesterone · Drug: Placebo

  • Experimental
    Treatment 4

    Combined Estradiol 0.25 mg / Progesterone 50 mg softgel capsule formulation and placebo, taken orally once a day for twelve months.

    Drug: Estradiol · Drug: Progesterone · Drug: Placebo

  • Placebo comparator
    Placebo

    Two Placebo softgel capsules taken orally once a day for twelve months.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 4

  2. Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 12

  3. Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 4

  4. Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 12

  5. Primary Safety Endpoint: Endometrial Protection - Hyperplasia

    Endometrial biopsies centrally evaluated by 2 primary pathologists using criteria from Blaustein's Pathology text. Pathologists classified bx into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus reached when 2 primary pathologist agreed on any of above categories; if primary pathologists disagreed on presence of hyperplasia, result of 3rd pathologist was utilized and final decision regarding presence of hyperplasia was based on diagnosis of majority. If all 3 reads disparate, final diagnosis based on most severe dx. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects w/biopsies following M11 meeting criteria specified plus all subjects w/biopsies positive for endometrial hyperplasia by any pathologists before M11.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Endometrial Protection - Hyperplasia

    Endometrial biopsies centrally evaluated by 3 primary pathologists using criteria described in Blaustein's Pathology text. Pathologists classified biopsy into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus was reached when the 2 of 3 pathologist readers agreed on any of the above categories; if all three reads were disparate, the final diagnosis was based on the most severe diagnosis. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects with biopsies following M11 meeting the criteria specified plus all subjects with biopsies positive for endometrial hyperplasia by any of the pathologists before M11.

    Time frame: Baseline and Month 12

  2. Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 1

  3. Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 2

  4. Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 3

  5. Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 4

  6. Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 5

  7. Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 6

  8. Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 7

  9. Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 8

  10. Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 9

  11. Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 10

  12. Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 11

  13. Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

    Time frame: Baseline and Week 12

  14. Severity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 1

  15. Severity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 2

  16. Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 3

  17. Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 4

  18. Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 5

  19. Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 6

  20. Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 7

  21. Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 8

  22. Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 9

  23. Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 10

  24. Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 11

  25. Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

    Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 12

  26. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 1

  27. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 2

  28. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 3

  29. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 4

  30. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 5

  31. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 6

  32. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 7

  33. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 8

  34. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 9

  35. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 10

  36. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 11

  37. Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

    Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

    Time frame: Baseline and Week 12

  38. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 1

  39. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 2

  40. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 3

  41. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 4

  42. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 5

  43. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 6

  44. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 7

  45. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 8

  46. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 9

  47. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 10

  48. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 11

  49. Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

    Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

    Time frame: Baseline and Week 12

  50. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe VMS from Baseline to Week 1.

    Time frame: Baseline and Week 1

  51. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2.

    Time frame: Baseline and Week 2

  52. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3.

    Time frame: Baseline and Week 3

  53. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4.

    Time frame: Baseline and Week 4

  54. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5.

    Time frame: Baseline and Week 5

  55. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6.

    Time frame: Baseline and Week 6

  56. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7.

    Time frame: Baseline and Week 7

  57. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8.

    Time frame: Baseline and Week 8

  58. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9.

    Time frame: Baseline and Week 9

  59. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10.

    Time frame: Baseline and Week 10

  60. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11.

    Time frame: Baseline and Week 11

  61. Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12.

    Time frame: Baseline and Week 12

  62. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1.

    Time frame: Baseline and Week 1

  63. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2.

    Time frame: Baseline and Week 2

  64. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3.

    Time frame: Baseline and Week 3

  65. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4.

    Time frame: Baseline and Week 4

  66. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5.

    Time frame: Baseline and Week 5

  67. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6.

    Time frame: Baseline and Week 6

  68. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7.

    Time frame: Baseline and Week 7

  69. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8.

    Time frame: Baseline and Week 8

  70. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9.

    Time frame: Baseline and Week 9

  71. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10.

    Time frame: Baseline and Week 10

  72. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11.

    Time frame: Baseline and Week 11

  73. Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 - (MITT-VMS)

    Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12.

    Time frame: Baseline and Week 12

  74. Clinical Global Impression (CGI) - Week 4 (MITT-VMS)

    The number and percentage of subjects for each possible response to the CGI at Week 4. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

    Time frame: Baseline and Week 4

  75. Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 4 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

    Time frame: Baseline and Week 4

  76. Clinical Global Impression (CGI) - Week 8 (MITT-VMS)

    The number and percentage of subjects for each possible response to the CGI at Week 8. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

    Time frame: Baseline and Week 8

  77. Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 8 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

    Time frame: Baseline and Week 8

  78. Clinical Global Impression (CGI) - Week 12 (MITT-VMS)

    The number and percentage of subjects for each possible response to the CGI at Week 12. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

    Time frame: Baseline and Week 12

  79. Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 12 (MITT-VMS)

    Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

    Time frame: Baseline and Week 12

  80. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 1 to 13

  81. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 2 to 13

  82. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 3 to 13

  83. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 4 to 13

  84. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 5 to 13

  85. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 6 to 13

  86. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 7 to 13

  87. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 8 to 13

  88. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 9 to 13

  89. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 10 to 13

  90. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 11 to 13

  91. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: Cycle 12 to 13

  92. Number of Subjects Without Bleeding for Consecutive Cycles

    No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

    Time frame: The 13th Cycle

  93. Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 1 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 1 to 13

  94. Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 2 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 2 to 13

  95. Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 3 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 3 to 13

  96. Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 4 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 4 to 13

  97. Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 5 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 5 to 13

  98. Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 6 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 6 to 13

  99. Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 7 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 7 to 13

  100. Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 8 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 8 to 13

  101. Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 9 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 9 to 13

  102. Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 10 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 10 to 13

  103. Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 11 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 11 to 13

  104. Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 13

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 12 to 13 was calculated and compared between active and placebo treatments.

    Time frame: Cycle 12 to 13

  105. Number of Subjects With Cumulative Amenorrhea From the 13th Cycle

    Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from the 13th Cycle was calculated and compared between active and placebo treatments.

    Time frame: The 13th Cycle

  106. Subject Incidence With Spotting - Trimester 1 (Safety Pop.)

    Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 1

  107. Subject Incidence With Spotting - Trimester 2 (Safety Pop.)

    Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 2

  108. Subject Incidence With Spotting - Trimester 3 (Safety Pop.)

    Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 3

  109. Subject Incidence With Spotting - Trimester 4 (Safety Pop.)

    Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 4

  110. Number of Days With Spotting - Trimester 1 (Safety Pop.)

    Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 1

  111. Number of Days With Spotting - Trimester 2 (Safety Pop.)

    Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 2

  112. Number of Days With Spotting - Trimester 3 (Safety Pop.)

    Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 3

  113. Number of Days With Spotting - Trimester 4 (Safety Pop.)

    Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 4

  114. Subject Incidence With Bleeding - Trimester 1 (Safety Pop.)

    Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 1

  115. Subject Incidence With Bleeding - Trimester 2 (Safety Pop.)

    Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 2

  116. Subject Incidence With Bleeding - Trimester 3 (Safety Pop.)

    Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 3

  117. Subject Incidence With Bleeding - Trimester 4 (Safety Pop.)

    Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 4

  118. Number of Days With Bleeding - Trimester 1 (Safety Pop.)

    Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 1

  119. Number of Days With Bleeding - Trimester 2 (Safety Pop.)

    Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 2

  120. Number of Days With Bleeding - Trimester 3 (Safety Pop.)

    Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 3

  121. Number of Days With Bleeding - Trimester 4 (Safety Pop.)

    Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

    Time frame: Trimester 4

  122. Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS)

    Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  123. Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS)

    Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  124. Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS)

    Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  125. Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS)

    Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  126. Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS)

    Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  127. Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS)

    Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  128. Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS)

    Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  129. Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS)

    Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  130. Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS)

    Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  131. Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS)

    Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  132. Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS)

    Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  133. Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS)

    Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  134. Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS)

    Changes in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  135. Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS)

    Changes in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  136. Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS)

    Changes in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  137. Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

    Time frame: Baseline and Week 12

  138. Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS)

    Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

    Time frame: Baseline and Month 6

  139. Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS)

    Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

    Time frame: Baseline and Month 12

  140. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  141. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS)

    Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  142. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS)

    Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  143. Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  144. Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS)

    Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  145. Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS)

    Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  146. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  147. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS)

    Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  148. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS)

    Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  149. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

    Time frame: Baseline and Week 12

  150. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS)

    Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

    Time frame: Baseline and Month 6

  151. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS)

    Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

    Time frame: Baseline and Month 12

  152. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  153. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS)

    Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  154. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS)

    Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  155. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  156. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS)

    Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  157. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS)

    Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  158. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS)

    Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  159. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS)

    Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  160. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS)

    Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  161. Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS)

    Change from Baseline (BL) to Week 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

    Time frame: Baseline and Week 12

  162. Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS)

    Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

    Time frame: Baseline and Month 6

  163. Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS)

    Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

    Time frame: Baseline and Month 12

  164. Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT)

    Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  165. Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT)

    Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  166. Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT)

    Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  167. Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT)

    Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  168. Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT)

    Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  169. Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT)

    Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  170. Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT)

    Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  171. Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT)

    Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  172. Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT)

    Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  173. Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT)

    Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  174. Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT)

    Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  175. Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT)

    Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  176. Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT)

    Change in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Week 12

  177. Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT)

    Change in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 6

  178. Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT)

    Change in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

    Time frame: Baseline and Month 12

  179. Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT)

    Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

    Time frame: Baseline and Week 12

  180. Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT)

    Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

    Time frame: Baseline and Month 6

  181. Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT)

    Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

    Time frame: Baseline and Month 12

  182. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT)

    Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  183. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT)

    Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  184. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT)

    Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  185. Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT)

    Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  186. Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT)

    Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  187. Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT)

    Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  188. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT)

    Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  189. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT)

    Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  190. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT)

    Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  191. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT)

    Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

    Time frame: Baseline and Week 12

  192. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT)

    Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

    Time frame: Baseline and Month 6

  193. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT)

    Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

    Time frame: Baseline and Month 12

  194. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT)

    Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  195. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT)

    Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  196. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT)

    Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  197. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT)

    Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  198. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT)

    Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  199. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT)

    Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  200. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT)

    Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Week 12

  201. Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT)

    Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 6

  202. Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT)

    Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

    Time frame: Baseline and Month 12

  203. Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT)

    Change from Baseline (BL) to Wk 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

    Time frame: Baseline and Week 12

  204. Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT)

    Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

    Time frame: Baseline and Month 6

  205. Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT)

    Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

    Time frame: Baseline and Month 12

07

Results

Posted May 6, 2019

Participant flow

Participant flow — Overall Study
MilestoneCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Started418426422427152
Completed28430531228193
Not completed13412111014659

Outcome measures

PrimaryCo-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 4
Reported as:
Mean · weekly hot flushes
Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)-40.6 ± 30.59-35.1 ± 29.14-33.6 ± 30.64-38.9 ± 31.04-26.4 ± 27.05
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -12.81 · 95% CI -19.29 to -6.32Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.013 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -8.07 · 95% CI -14.46 to -1.68Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.141 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -4.81 · 95% CI -11.21 to 1.59Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -10.40 · 95% CI -16.73 to -4.08Adjusted for baseline using MMRM
PrimaryCo-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 12
Reported as:
Mean · weekly hot flushes
Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Co-Primary Efficacy Endpoint: Frequency of Moderate to Severe Vasomotor Symptoms (MITT-VMS)-55.1 ± 31.36-53.7 ± 31.93-50.2 ± 31.35-52.4 ± 33.90-40.2 ± 29.79
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -16.58 · 95% CI -23.33 to -9.82Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -15.07 · 95% CI -21.72 to -8.42Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -10.79 · 95% CI -17.48 to -4.10Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -11.71 · 95% CI -18.31 to -5.11Adjusted for baseline using MMRM
PrimaryCo-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 4
Reported as:
Mean · scores on a scale
Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)-0.48 ± 0.547-0.51 ± 0.563-0.40 ± 0.469-0.44 ± 0.514-0.34 ± 0.386
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.031 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -0.13 · 95% CI -0.25 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -0.17 · 95% CI -0.28 to -0.05Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.401 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -0.05 · 95% CI -0.17 to 0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.100 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -0.10 · 95% CI -0.21 to 0.02Adjusted for baseline using MMRM
PrimaryCo-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 12
Reported as:
Mean · scores on a scale
Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Co-Primary Efficacy Endpoint: Severity of Moderate to Severe Vasomotor Symptoms (MITT-VMS)-1.12 ± 0.963-0.90 ± 0.783-0.76 ± 0.744-0.71 ± 0.806-0.56 ± 0.603
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.57 · 95% CI -0.77 to -0.38Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.39 · 95% CI -0.59 to -0.20Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.018 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.24 · 95% CI -0.43 to -0.04Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.096 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.16 · 95% CI -0.36 to 0.03Adjusted for baseline using MMRM
PrimaryPrimary Safety Endpoint: Endometrial Protection - Hyperplasia

Endometrial biopsies centrally evaluated by 2 primary pathologists using criteria from Blaustein's Pathology text. Pathologists classified bx into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus reached when 2 primary pathologist agreed on any of above categories; if primary pathologists disagreed on presence of hyperplasia, result of 3rd pathologist was utilized and final decision regarding presence of hyperplasia was based on diagnosis of majority. If all 3 reads disparate, final diagnosis based on most severe dx. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects w/biopsies following M11 meeting criteria specified plus all subjects w/biopsies positive for endometrial hyperplasia by any pathologists before M11.

Time frame:
Baseline and Month 12
Reported as:
Count of participants · Participants
Primary Safety Endpoint: Endometrial Protection - Hyperplasia
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Primary Safety Endpoint: Endometrial Protection - Hyperplasia00000
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Combined Estradiol 0.5 mg / Progesterone 100 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Combined Estradiol 0.5 mg / Progesterone 50 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Combined Estradiol 0.25 mg / Progesterone 50 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Placebo · Incidence rate: 0This calculation is based on a binomial distribution.
SecondaryEndometrial Protection - Hyperplasia

Endometrial biopsies centrally evaluated by 3 primary pathologists using criteria described in Blaustein's Pathology text. Pathologists classified biopsy into 1 of following 3 categories: Cat.1: Non-endometrial malignancy/non-hyperplasia; Cat.2: Endometrial hyperplasia; Cat.3: Endometrial malignancy. Consensus was reached when the 2 of 3 pathologist readers agreed on any of the above categories; if all three reads were disparate, the final diagnosis was based on the most severe diagnosis. Incidence rate calculated as: I=A/B where I=incidence rate at M12 evaluation, A=all new subjects with biopsies positive for endometrial hyperplasia during study but post-Baseline, B=all subjects with biopsies following M11 meeting the criteria specified plus all subjects with biopsies positive for endometrial hyperplasia by any of the pathologists before M11.

Time frame:
Baseline and Month 12
Reported as:
Count of participants · Participants
Endometrial Protection - Hyperplasia
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Endometrial Protection - Hyperplasia00000
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Combined Estradiol 0.5 mg / Progesterone 100 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Combined Estradiol 0.5 mg / Progesterone 50 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Combined Estradiol 0.25 mg / Progesterone 50 mg · Incidence rate: 0This calculation is based on a binomial distribution.
  • Placebo · Incidence rate: 0This calculation is based on a binomial distribution.
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 1
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)-12.2 ± 20.10-11.5 ± 20.19-11.0 ± 20.94-16.3 ± 22.28-13.0 ± 21.25
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.588 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 1.36 · 95% CI -3.57 to 6.30Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.601 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 1.29 · 95% CI -3.56 to 6.15Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.202 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): 3.17 · 95% CI -1.71 to 8.06Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.431 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): -1.93 · 95% CI -6.76 to 2.89Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 2
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)-26.6 ± 27.67-21.2 ± 24.79-19.0 ± 28.32-25.4 ± 26.63-21.3 ± 24.75
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.154 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -4.35 · 95% CI -10.34 to 1.64Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.956 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -0.17 · 95% CI -6.06 to 5.73Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.240 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): 3.54 · 95% CI -2.37 to 9.46Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.353 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): -2.77 · 95% CI -8.62 to 3.08Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 3
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)-34.3 ± 29.22-29.0 ± 26.73-28.1 ± 28.18-33.6 ± 27.76-25.1 ± 27.26
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -8.56 · 95% CI -14.75 to -2.36Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.227 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -3.76 · 95% CI -9.86 to 2.35Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.597 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): -1.65 · 95% CI -7.77 to 4.47Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.019 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): -7.24 · 95% CI -13.28 to -1.19Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 4
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)-40.6 ± 30.59-35.1 ± 29.14-33.6 ± 30.64-38.9 ± 31.04-26.4 ± 27.05
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -12.81 · 95% CI -19.29 to -6.32Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.013 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -8.07 · 95% CI -14.46 to -1.68Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.141 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -4.81 · 95% CI -11.21 to 1.59Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -10.40 · 95% CI -16.73 to -4.08Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 5
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)-45.9 ± 32.31-39.5 ± 28.53-37.1 ± 30.64-43.5 ± 33.31-31.6 ± 28.96
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -15.59 · 95% CI -22.16 to -9.02Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -9.88 · 95% CI -16.34 to -3.41Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.075 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): -5.90 · 95% CI -12.40 to 0.59Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): -12.05 · 95% CI -18.47 to -5.64Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 6
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)-49.4 ± 32.76-41.7 ± 29.97-40.1 ± 33.62-45.5 ± 33.14-32.7 ± 28.53
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -17.87 · 95% CI -24.57 to -11.05Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -11.35 · 95% CI -18.00 to -4.70Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.022 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -7.82 · 95% CI -14.50 to -1.14Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -12.51 · 95% CI -19.11 to -5.91Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 7
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)-51.5 ± 31.51-45.0 ± 30.73-43.8 ± 33.20-47.7 ± 32.18-33.4 ± 29.37
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -17.75 · 95% CI -24.45 to -11.06Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -13.29 · 95% CI -19.88 to -6.70Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -10.22 · 95% CI -16.83 to -3.60Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -13.61 · 95% CI -20.15 to -7.07Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 8
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)-52.3 ± 31.63-46.8 ± 30.64-45.4 ± 32.55-48.4 ± 32.82-36.0 ± 30.66
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -16.63 · 95% CI -23.35 to -9.91Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -12.97 · 95% CI -19.58 to -6.36Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -9.63 · 95% CI -16.27 to -2.99Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -11.97 · 95% CI -18.53 to -5.41Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 9
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)-52.6 ± 32.57-50.5 ± 31.01-47.4 ± 30.13-50.1 ± 33.92-36.4 ± 29.09
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -17.12 · 95% CI -23.79 to -10.44Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -15.58 · 95% CI -22.15 to -9.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -11.05 · 95% CI -17.65 to -4.44Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -13.02 · 95% CI -19.54 to -6.50Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 10
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)-53.2 ± 32.58-51.9 ± 32.79-49.0 ± 30.24-50.6 ± 33.36-37.1 ± 29.74
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -16.80 · 95% CI -23.58 to -10.03Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -15.66 · 95% CI -22.32 to -8.99Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -11.20 · 95% CI -17.90 to -4.49Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -12.16 · 95% CI -18.78 to -5.55Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 11
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)-53.7 ± 32.21-52.0 ± 31.24-49.4 ± 30.71-50.9 ± 34.33-36.7 ± 30.32
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -18.11 · 95% CI -24.92 to -11.29Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -16.45 · 95% CI -23.17 to -9.74Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -12.41 · 95% CI -19.15 to -5.66Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -13.60 · 95% CI -20.26 to -6.93Adjusted for baseline using MMRM
SecondaryFrequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of moderate to severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of moderate to severe hot flushes for the subject week.

Time frame:
Baseline and Week 12
Reported as:
Mean · weekly hot flushes
Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)-55.1 ± 31.36-53.7 ± 31.93-50.2 ± 31.35-52.4 ± 33.90-40.2 ± 29.79
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -16.58 · 95% CI -23.33 to -9.82Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -15.07 · 95% CI -21.72 to -8.42Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -10.79 · 95% CI -17.48 to -4.10Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -11.71 · 95% CI -18.31 to -5.11Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 1
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)-0.24 ± 0.305-0.25 ± 0.270-0.23 ± 0.264-0.25 ± 0.327-0.25 ± 0.257
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.801 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 0.01 · 95% CI -0.06 to 0.08Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.991 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 0.00 · 95% CI -0.07 to 0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.642 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): 0.02 · 95% CI -0.05 to 0.08Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.928 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): -0.00 · 95% CI -0.07 to 0.06Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 2
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)-0.34 ± 0.411-0.34 ± 0.390-0.27 ± 0.354-0.29 ± 0.314-0.28 ± 0.310
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.231 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -0.05 · 95% CI -0.14 to 0.03Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.173 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -0.06 · 95% CI -0.14 to 0.03Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.717 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): 0.02 · 95% CI -0.07 to 0.10Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.849 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): -0.01 · 95% CI -0.09 to 0.07Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 3
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)-0.43 ± 0.514-0.44 ± 0.437-0.32 ± 0.410-0.37 ± 0.424-0.32 ± 0.372
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.039 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -0.11 · 95% CI -0.21 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.030 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -0.11 · 95% CI -0.21 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.946 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): 0.00 · 95% CI -0.10 to 0.10Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.309 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): -0.05 · 95% CI -0.15 to 0.05Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 4
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)-0.48 ± 0.547-0.51 ± 0.563-0.40 ± 0.469-0.44 ± 0.514-0.34 ± 0.386
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.031 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -0.13 · 95% CI -0.25 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -0.17 · 95% CI -0.28 to -0.05Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.401 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -0.05 · 95% CI -0.17 to 0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.100 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -0.10 · 95% CI -0.21 to 0.02Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 5
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)-0.64 ± 0.702-0.56 ± 0.558-0.44 ± 0.463-0.53 ± 0.610-0.42 ± 0.551
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -0.23 · 95% CI -0.37 to -0.09Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.034 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -0.15 · 95% CI -0.28 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.790 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): -0.02 · 95% CI -0.16 to 0.12Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.086 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): -0.12 · 95% CI -0.25 to 0.02Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 6
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)-0.80 ± 0.840-0.61 ± 0.640-0.54 ± 0.578-0.63 ± 0.763-0.45 ± 0.573
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -0.36 · 95% CI -0.53 to -0.20Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.030 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -0.18 · 95% CI -0.34 to -0.02Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.247 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -0.10 · 95% CI -0.26 to 0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.022 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -0.19 · 95% CI -0.35 to -0.03Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 7
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)-0.81 ± 0.793-0.69 ± 0.694-0.63 ± 0.637-0.64 ± 0.764-0.44 ± 0.483
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -0.37 · 95% CI -0.54 to -0.20Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -0.25 · 95% CI -0.42 to -0.09Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.031 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -0.18 · 95% CI -0.34 to -0.02Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.016 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -0.20 · 95% CI -0.36 to -0.04Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 8
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)-0.88 ± 0.854-0.70 ± 0.642-0.65 ± 0.685-0.64 ± 0.745-0.51 ± 0.563
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -0.38 · 95% CI -0.55 to -0.21Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.008 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -0.23 · 95% CI -0.40 to -0.06Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.087 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -0.15 · 95% CI -0.32 to 0.02Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.092 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -0.14 · 95% CI -0.31 to 0.02Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 9
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)-0.96 ± 0.892-0.74 ± 0.699-0.73 ± 0.720-0.71 ± 0.772-0.48 ± 0.536
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -0.48 · 95% CI -0.66 to -0.30Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -0.29 · 95% CI -0.47 to -0.12Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -0.24 · 95% CI -0.42 to -0.06Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -0.24 · 95% CI -0.42 to -0.07Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 10
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)-1.05 ± 0.953-0.77 ± 0.727-0.78 ± 0.769-0.62 ± 0.739-0.53 ± 0.575
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -0.52 · 95% CI -0.71 to -0.33Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -0.28 · 95% CI -0.46 to -0.09Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.016 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -0.23 · 95% CI -0.41 to -0.04Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.310 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -0.10 · 95% CI -0.28 to 0.09Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 11
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)-1.04 ± 0.931-0.86 ± 0.777-0.78 ± 0.782-0.68 ± 0.767-0.54 ± 0.566
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -0.53 · 95% CI -0.72 to -0.34Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -0.37 · 95% CI -0.56 to -0.19Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.011 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -0.25 · 95% CI -0.44 to -0.06Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.076 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -0.17 · 95% CI -0.36 to 0.02Adjusted for baseline using MMRM
SecondarySeverity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

Mean change in severity of moderate to severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score = (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of moderate to severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 12
Reported as:
Mean · scores on a scale
Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)-1.12 ± 0.963-0.90 ± 0.783-0.76 ± 0.744-0.71 ± 0.806-0.56 ± 0.603
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.57 · 95% CI -0.77 to -0.38Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.39 · 95% CI -0.59 to -0.20Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.018 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.24 · 95% CI -0.43 to -0.04Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.096 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.16 · 95% CI -0.36 to 0.03Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 1
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)-12.9 ± 22.12-12.4 ± 23.94-12.5 ± 24.62-17.7 ± 27.78-12.2 ± 23.76
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.865 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 0.49 · 95% CI -5.16 to 6.14Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.847 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 0.55 · 95% CI -5.01 to 6.10Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.463 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): 2.09 · 95% CI -3.50 to 7.68Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.207 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): -3.55 · 95% CI -9.07 to 1.97Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 2
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)-28.2 ± 29.45-22.4 ± 30.53-21.8 ± 31.66-27.8 ± 32.35-21.7 ± 27.45
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.140 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -5.07 · 95% CI -11.80 to 1.67Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.982 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -0.08 · 95% CI -6.70 to 6.55Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.492 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): 2.33 · 95% CI -4.32 to 8.98Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.216 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): -4.14 · 95% CI -10.72 to 2.43Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 3
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)-37.4 ± 32.33-30.7 ± 32.00-31.3 ± 30.79-35.6 ± 33.52-25.8 ± 30.41
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -10.38 · 95% CI -17.26 to -3.50Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.277 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -3.75 · 95% CI -10.53 to 3.02Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.394 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): -2.95 · 95% CI -9.75 to 3.84Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.022 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): -7.86 · 95% CI -14.58 to -1.15Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 4
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)-44.4 ± 34.53-37.7 ± 35.38-35.4 ± 34.58-41.5 ± 37.40-26.8 ± 30.52
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -15.32 · 95% CI -22.75 to -7.89Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.017 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -8.92 · 95% CI -16.24 to -1.60Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.223 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -4.56 · 95% CI -11.90 to 2.78Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -11.32 · 95% CI -18.57 to -4.07Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 5
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)-49.9 ± 33.86-42.3 ± 34.15-40.1 ± 32.52-46.8 ± 39.88-33.3 ± 33.49
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -17.47 · 95% CI -24.65 to -10.28Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -10.26 · 95% CI -17.33 to -3.18Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.087 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): -6.21 · 95% CI -13.31 to 0.89Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): -12.66 · 95% CI -19.68 to -5.65Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 6
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)-53.9 ± 35.34-44.9 ± 36.12-43.0 ± 34.84-49.4 ± 40.28-34.1 ± 33.32
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -20.32 · 95% CI -27.77 to -12.87Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -12.61 · 95% CI -19.95 to -5.28Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.027 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -8.33 · 95% CI -15.70 to -0.96Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -13.85 · 95% CI -21.13 to -6.58Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 7
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)-56.1 ± 34.55-48.8 ± 36.92-47.2 ± 34.39-51.5 ± 39.69-33.4 ± 33.71
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -21.45 · 95% CI -28.87 to -14.04Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -16.10 · 95% CI -23.39 to -8.80Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -12.01 · 95% CI -19.34 to -4.68Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -15.73 · 95% CI -22.97 to -8.49Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 8
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)-57.1 ± 35.91-50.6 ± 37.73-49.5 ± 34.34-52.4 ± 40.65-36.9 ± 35.53
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -20.52 · 95% CI -28.06 to -12.97Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -15.37 · 95% CI -22.80 to -7.95Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -11.49 · 95% CI -18.95 to -4.03Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -13.82 · 95% CI -21.19 to -6.46Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 9
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)-57.6 ± 36.43-54.7 ± 38.76-52.8 ± 33.68-54.5 ± 41.89-38.3 ± 35.04
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -20.34 · 95% CI -27.93 to -12.74Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -17.92 · 95% CI -25.39 to -10.45Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -12.97 · 95% CI -20.49 to -5.46Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -14.28 · 95% CI -21.70 to -6.87Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 10
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)-58.5 ± 36.86-56.1 ± 39.97-53.7 ± 34.39-55.7 ± 41.55-38.3 ± 35.52
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -21.01 · 95% CI -28.72 to -13.29Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -18.37 · 95% CI -25.96 to -10.78Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -13.03 · 95% CI -20.66 to -5.39Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -14.65 · 95% CI -22.19 to -7.12Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 11
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)-58.8 ± 36.58-57.0 ± 38.81-54.2 ± 34.38-56.1 ± 42.45-38.4 ± 35.85
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -21.83 · 95% CI -29.57 to -14.08Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -19.40 · 95% CI -27.02 to -11.77Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -13.98 · 95% CI -21.65 to -6.32Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -15.66 · 95% CI -23.23 to -8.10Adjusted for baseline using MMRM
SecondaryFrequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

Mean change in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The weekly frequency of mild, moderate and severe hot flushes was calculated from the daily diary record using a forward counting process of 7 day intervals beginning with the baseline date. Weekly frequency equals total number of mild, moderate and severe hot flushes for the subject week.

Time frame:
Baseline and Week 12
Reported as:
Mean · weekly hot flushes
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)-60.3 ± 36.42-58.8 ± 39.59-54.8 ± 34.94-57.0 ± 41.71-41.7 ± 36.35
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -20.61 · 95% CI -28.32 to -12.89Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -18.24 · 95% CI -25.84 to -10.65Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -12.62 · 95% CI -20.26 to -4.98Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -13.97 · 95% CI -21.51 to -6.43Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 1. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 1
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 (MITT-VMS)-0.06 ± 0.211-0.05 ± 0.206-0.02 ± 0.197-0.08 ± 0.305-0.07 ± 0.200
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.676 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 0.01 · 95% CI -0.04 to 0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.436 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1) · Mean difference (final values): 0.02 · 95% CI -0.03 to 0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.106 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): 0.04 · 95% CI -0.01 to 0.10Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.752 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1) · Mean difference (final values): -0.01 · 95% CI -0.06 to 0.04Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 2. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 2
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 (MITT-VMS)-0.16 ± 0.349-0.14 ± 0.342-0.06 ± 0.309-0.12 ± 0.288-0.11 ± 0.275
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.193 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -0.05 · 95% CI -0.12 to 0.02Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.319 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2) · Mean difference (final values): -0.04 · 95% CI -0.11 to 0.04Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.239 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): 0.04 · 95% CI -0.03 to 0.12Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.720 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2) · Mean difference (final values): -0.01 · 95% CI -0.09 to 0.06Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 3. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 3
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 (MITT-VMS)-0.25 ± 0.480-0.24 ± 0.402-0.11 ± 0.379-0.20 ± 0.412-0.15 ± 0.350
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.030 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -0.11 · 95% CI -0.20 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.060 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3) · Mean difference (final values): -0.09 · 95% CI -0.19 to 0.00Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.506 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): 0.03 · 95% CI -0.06 to 0.13Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.232 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3) · Mean difference (final values): -0.06 · 95% CI -0.15 to 0.04Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 4. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 4
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 (MITT-VMS)-0.31 ± 0.527-0.31 ± 0.540-0.19 ± 0.434-0.27 ± 0.507-0.17 ± 0.368
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.027 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -0.13 · 95% CI -0.24 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.011 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4) · Mean difference (final values): -0.15 · 95% CI -0.26 to -0.03Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.710 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -0.02 · 95% CI -0.13 to 0.09Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.072 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4) · Mean difference (final values): -0.10 · 95% CI -0.21 to 0.01Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 5. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 5
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 (MITT-VMS)-0.46 ± 0.680-0.37 ± 0.546-0.23 ± 0.441-0.36 ± 0.619-0.24 ± 0.524
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -0.23 · 95% CI -0.36 to -0.09Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.062 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5) · Mean difference (final values): -0.13 · 95% CI -0.26 to 0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.886 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): 0.01 · 95% CI -0.12 to 0.14Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.067 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5) · Mean difference (final values): -0.12 · 95% CI -0.26 to 0.01Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 6. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 6
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 (MITT-VMS)-0.62 ± 0.835-0.42 ± 0.627-0.33 ± 0.588-0.46 ± 0.775-0.27 ± 0.548
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -0.36 · 95% CI -0.53 to -0.20Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.053 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6) · Mean difference (final values): -0.16 · 95% CI -0.32 to 0.00Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.413 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -0.07 · 95% CI -0.23 to 0.09Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.018 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6) · Mean difference (final values): -0.19 · 95% CI -0.35 to -0.03Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 7. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 7
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 (MITT-VMS)-0.65 ± 0.798-0.50 ± 0.687-0.42 ± 0.660-0.47 ± 0.773-0.27 ± 0.469
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -0.37 · 95% CI -0.54 to -0.20Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7) · Mean difference (final values): -0.23 · 95% CI -0.40 to -0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.072 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -0.15 · 95% CI -0.32 to 0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.014 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7) · Mean difference (final values): -0.20 · 95% CI -0.37 to -0.04Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 8. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 8
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 (MITT-VMS)-0.70 ± 0.858-0.51 ± 0.633-0.44 ± 0.701-0.47 ± 0.750-0.33 ± 0.545
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -0.38 · 95% CI -0.55 to -0.21Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.016 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8) · Mean difference (final values): -0.21 · 95% CI -0.37 to -0.04Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.169 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -0.12 · 95% CI -0.29 to 0.05Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.081 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8) · Mean difference (final values): -0.15 · 95% CI -0.31 to 0.02Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 9. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 9
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 (MITT-VMS)-0.78 ± 0.909-0.55 ± 0.708-0.51 ± 0.735-0.54 ± 0.780-0.31 ± 0.515
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -0.48 · 95% CI -0.66 to -0.30Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9) · Mean difference (final values): -0.27 · 95% CI -0.45 to -0.10Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.022 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -0.21 · 95% CI -0.39 to -0.03Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9) · Mean difference (final values): -0.25 · 95% CI -0.43 to -0.07Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 10. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 10
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 (MITT-VMS)-0.87 ± 0.970-0.58 ± 0.731-0.57 ± 0.785-0.45 ± 0.754-0.35 ± 0.557
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -0.52 · 95% CI -0.71 to -0.33Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10) · Mean difference (final values): -0.26 · 95% CI -0.44 to -0.07Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.038 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -0.20 · 95% CI -0.39 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.283 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10) · Mean difference (final values): -0.10 · 95% CI -0.29 to 0.08Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 11. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 11
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 (MITT-VMS)-0.86 ± 0.950-0.67 ± 0.788-0.56 ± 0.800-0.50 ± 0.776-0.36 ± 0.543
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -0.53 · 95% CI -0.72 to -0.34Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11) · Mean difference (final values): -0.35 · 95% CI -0.54 to -0.16Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.027 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -0.22 · 95% CI -0.41 to -0.02Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.071 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11) · Mean difference (final values): -0.17 · 95% CI -0.36 to 0.01Adjusted for baseline using MMRM
SecondarySeverity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

Mean change in severity of mild, moderate and severe vasomotor symptoms at Baseline to mild, moderate to severe vasomotor symptoms at Week 12. The baseline was the most recent 7 consecutive days of data prior to randomization. The severity score was derived as follows: mild = 1, moderate = 2, severe = 3. Baseline Weekly Severity Score =(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days). On Treatment Weekly Severity Score = \[(number of mild hot flushes for 7 days) x 1 + (number of moderate hot flushes for 7 days) x 2 + (number of severe hot flushes for 7 days) x 3\] / (total number of mild, moderate and severe hot flushes over 7 days).

Time frame:
Baseline and Week 12
Reported as:
Mean · scores on a scale
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
scores on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Severity of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 (MITT-VMS)-0.94 ± 0.986-0.71 ± 0.784-0.54 ± 0.761-0.54 ± 0.824-0.39 ± 0.585
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.57 · 95% CI -0.77 to -0.37Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.37 · 95% CI -0.57 to -0.18Adjusted for baseline using MMRM
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.039 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.21 · 95% CI -0.40 to -0.01Adjusted for baseline using MMRM
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.088 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.17 · 95% CI -0.36 to 0.03Adjusted for baseline using MMRM
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe VMS from Baseline to Week 1.

Time frame:
Baseline and Week 1
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 1 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction1517152516
>=75% Reduction34451
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.850 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.622 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 1.000 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.374 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.706 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.372 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.316 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.221 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 2.

Time frame:
Baseline and Week 2
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 2 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction4435344935
>=75% Reduction211215206
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.283 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.680 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.232 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.677 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.073 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.301 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.013 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 3.

Time frame:
Baseline and Week 3
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 3 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction6859547142
>=75% Reduction3824212915
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.003 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.135 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.231 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.377 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.478 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.015 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.100 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4.

Time frame:
Baseline and Week 4
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 4 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction8270748141
>=75% Reduction5534324515
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.017 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.025 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 5.

Time frame:
Baseline and Week 5
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 5 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9380749055
>=75% Reduction5547385427
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.066 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.055 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.174 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.319 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.008 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 6.

Time frame:
Baseline and Week 6
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 6 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9885829555
>=75% Reduction6851475630
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.019 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.061 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.026 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.104 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.018 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 7.

Time frame:
Baseline and Week 7
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 7 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction96938810158
>=75% Reduction7163565832
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.017 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.025 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.037 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8.

Time frame:
Baseline and Week 8
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 8 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction102989010060
>=75% Reduction7864596237
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.016 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.012 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.053 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.074 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 9.

Time frame:
Baseline and Week 9
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 9 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction981079210163
>=75% Reduction7273636335
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.015 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 10.

Time frame:
Baseline and Week 10
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 10 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9510210010168
>=75% Reduction7869626437
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.018 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.021 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 11.

Time frame:
Baseline and Week 11
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 11 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction951059710459
>=75% Reduction7974656834
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11)
SecondaryReduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Reduction of Frequency of Moderate to Severe Vasomotor Symptoms - Week 12 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction98104949967
>=75% Reduction8475666837
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.015 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 1.

Time frame:
Baseline and Week 1
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 1 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction1410121910
>=75% Reduction22141
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.523 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 1.000 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.821 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 1.000 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.828 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 1)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.239 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.377 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 1)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 2.

Time frame:
Baseline and Week 2
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 2 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction3624303921
>=75% Reduction1579174
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.036 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.015 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 1.000 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.546 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.352 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.261 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 2)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.058 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.011 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 2)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 3.

Time frame:
Baseline and Week 3
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 3 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction6349506133
>=75% Reduction331415226
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.115 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.110 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.089 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.074 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 3)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.011 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.008 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 3)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 4.

Time frame:
Baseline and Week 4
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 4 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction8062657335
>=75% Reduction442824336
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.011 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 5.

Time frame:
Baseline and Week 5
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 5 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction8672698247
>=75% Reduction4834273713
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.048 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.063 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.058 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 5)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 5)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 6.

Time frame:
Baseline and Week 6
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 6 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9278768352
>=75% Reduction6139394316
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.050 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.048 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 6)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.020 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 6)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 7.

Time frame:
Baseline and Week 7
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 7 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9387819549
>=75% Reduction6346444716
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 7)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 7)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 8.

Time frame:
Baseline and Week 8
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 8 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9885909354
>=75% Reduction6453455120
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.013 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 9.

Time frame:
Baseline and Week 9
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 9 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9595919458
>=75% Reduction6963545622
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 9)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 9)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 10.

Time frame:
Baseline and Week 10
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 10 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9394929354
>=75% Reduction7360575723
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 10)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 10)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 11.

Time frame:
Baseline and Week 11
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 11 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9497949555
>=75% Reduction7164526226
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 11)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 11)
SecondaryReduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 - (MITT-VMS)

Number of Subjects with \>=50%, and separately, \>=75% reduction in frequency of mild, moderate and severe vasomotor symptoms from Baseline to Week 12.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Reduction of Frequency of Mild, Moderate and Severe Vasomotor Symptoms - Week 12 - (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
>=50% Reduction9794909555
>=75% Reduction7364505832
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.056 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.017 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12)
SecondaryClinical Global Impression (CGI) - Week 4 (MITT-VMS)

The number and percentage of subjects for each possible response to the CGI at Week 4. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

Time frame:
Baseline and Week 4
Reported as:
Count of participants · Participants
Clinical Global Impression (CGI) - Week 4 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
(Very) Much Improved8671727541
Minimally Improved3749495149
No Change or Worse1321232235
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.005 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 4)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.007 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 4)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 4)
SecondaryMean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 4 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 4 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

Time frame:
Baseline and Week 4
Reported as:
Mean · weekly hot flushes
Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 4 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
(Very) Much Improved-52.5 ± 27.28-48.6 ± 28.87-46.2 ± 31.23-55.7 ± 25.69-47.0 ± 24.17
Minimally Improved-24.1 ± 23.87-25.9 ± 21.43-29.2 ± 23.26-28.9 ± 26.08-26.8 ± 17.68
No Change or Worse-6.5 ± 23.08-6.6 ± 16.39-2.7 ± 16.22-5.3 ± 21.97-5.3 ± 13.68
SecondaryClinical Global Impression (CGI) - Week 8 (MITT-VMS)

The number and percentage of subjects for each possible response to the CGI at Week 8. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

Time frame:
Baseline and Week 8
Reported as:
Count of participants · Participants
Clinical Global Impression (CGI) - Week 8 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
(Very) Much Improved101103989362
Minimally Improved2324233525
No Change or Worse612131330
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 8)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.001 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 8)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.002 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 8)
SecondaryMean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 8 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 8 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

Time frame:
Baseline and Week 8
Reported as:
Mean · weekly hot flushes
Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 8 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
(Very) Much Improved-60.8 ± 28.49-55.1 ± 29.27-55.4 ± 29.06-57.8 ± 30.38-52.6 ± 24.62
Minimally Improved-28.7 ± 18.93-27.3 ± 25.22-27.2 ± 22.79-36.8 ± 24.81-27.0 ± 13.54
No Change or Worse-0.2 ± 28.80-15.2 ± 13.41-1.6 ± 19.93-7.4 ± 21.48-7.1 ± 21.46
SecondaryClinical Global Impression (CGI) - Week 12 (MITT-VMS)

The number and percentage of subjects for each possible response to the CGI at Week 12. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

Time frame:
Baseline and Week 12
Reported as:
Count of participants · Participants
Clinical Global Impression (CGI) - Week 12 (MITT-VMS)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
(Very) Much Improved1019710210162
Minimally Improved1729222426
No Change or Worse5771428
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = <0.001 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.002 (P-value is derived from comparing % Very Much Improved+Much Improved between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12)
SecondaryMean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 12 (MITT-VMS)

Mean change in frequency of moderate to severe vasomotor symptoms from Baseline to Week 12 for the respective CGI category. The CGI score is a seven point scale where subjects were asked to rate the total improvement, whether or not in her judgment it was due entirely to drug treatment, compared to her condition at admission to the study. Scale: Very much improved, Much improved, Minimally improved, No change, Minimally worse, Much worse, Very much worse. Results for the top two responses (Very Much Improved and Much Improved) and No Change or Worsening (Minimally worse, Much worse, Very much worse) were combined for each group and active treatment groups compare to placebo.

Time frame:
Baseline and Week 12
Reported as:
Mean · weekly hot flushes
Mean Change in Frequency of Moderate to Severe VMS for the Respective CGI Category - Week 12 (MITT-VMS)
weekly hot flushesCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
(Very) Much Improved-58.8 ± 30.71-60.0 ± 28.37-58.2 ± 29.42-59.9 ± 28.01-56.2 ± 26.50
Minimally Improved-35.9 ± 24.78-34.9 ± 40.36-28.8 ± 21.99-40.6 ± 37.36-35.7 ± 19.55
No Change or Worse-30.7 ± 32.89-38.8 ± 18.99-8.6 ± 18.42-8.3 ± 31.84-9.2 ± 16.77
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 1 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles20425126323982
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.000
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.122
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.280
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.692
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 2 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles20925626524484
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.000
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.069
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.131
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.661
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 3 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles21425826724685
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.000
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.040
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.082
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.495
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 4 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles21726127325386
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.000
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.032
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.137
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.792
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 5 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles22426527825386
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.000
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.067
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.260
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.792
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 6 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles22726828025686
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.095
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.352
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 7 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles23727128225687
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.002
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.075
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.225
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.769
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 8 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles24227628525888
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.002
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.084
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.183
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.738
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 9 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles24527928825988
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.006
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.125
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.386
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.737
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 10 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles24828129226188
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.009
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.183
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.745
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 11 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles25128429426188
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.035
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.536
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
Cycle 12 to 13
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles26028429526088
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.261
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.536
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects Without Bleeding for Consecutive Cycles

No bleeding was defined as the absence of bleeding. Cumulative rates for no bleeding was defined as the percentage of women who reported consecutive cycles of no bleeding for a given cycle of time.

Time frame:
The 13th Cycle
Reported as:
Count of participants · Participants
Number of Subjects Without Bleeding for Consecutive Cycles
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects Without Bleeding for Consecutive Cycles26828729626189
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.463
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.687
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 1 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 1 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 1 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 1 to 1315620220719671
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.048
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.049
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.328
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 2 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 2 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 2 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 2 to 1316622021521274
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.123
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.030
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.649
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 3 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 3 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 3 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 3 to 1317422722521877
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.059
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.023
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.426
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 4 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 4 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 4 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 4 to 1317723623322980
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.044
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.011
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.481
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 5 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 5 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 5 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 5 to 1318324424023480
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.110
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.045
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.853
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 6 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 6 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 6 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 6 to 1318625024923680
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.245
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.145
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 7 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 7 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 7 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 7 to 1320025325523882
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.163
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.091
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.693
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 8 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 8 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 8 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 8 to 1320926226224284
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.178
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.097
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.522
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 9 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 9 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 9 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 9 to 1321426726624684
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.315
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.181
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.821
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 10 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 10 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 10 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 10 to 1322227127324885
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.387
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.215
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.639
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 11 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 11 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 11 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 11 to 1323127527724985
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.008
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.643
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.501
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects With Cumulative Amenorrhea From Cycle 12 to 13

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from Cycle 12 to 13 was calculated and compared between active and placebo treatments.

Time frame:
Cycle 12 to 13
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 13
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From Cycle 12 to 1323827827825286
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.013
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.616
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.352
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000
SecondaryNumber of Subjects With Cumulative Amenorrhea From the 13th Cycle

Cumulative amenorrhea is defined as the absence of bleeding or spotting for a cumulative period. Cumulative rates of amenorrhea were defined as the percentage of women who reported consecutive cycles of amenorrhea for a given cycle of time. Within each treatment arm, the percentage of subjects with cumulative amenorrhea from the 13th Cycle was calculated and compared between active and placebo treatments.

Time frame:
The 13th Cycle
Reported as:
Count of participants · Participants
Number of Subjects With Cumulative Amenorrhea From the 13th Cycle
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Subjects With Cumulative Amenorrhea From the 13th Cycle24928228325488
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.023
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.535
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.183
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.738
SecondarySubject Incidence With Spotting - Trimester 1 (Safety Pop.)

Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 1
Reported as:
Count of participants · Participants
Subject Incidence With Spotting - Trimester 1 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Spotting - Trimester 1 (Safety Pop.)9074685810
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 1)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 1)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.012 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 1)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.032 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 1)
SecondarySubject Incidence With Spotting - Trimester 2 (Safety Pop.)

Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 2
Reported as:
Count of participants · Participants
Subject Incidence With Spotting - Trimester 2 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Spotting - Trimester 2 (Safety Pop.)764048244
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 2)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.022 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 2)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 2)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.256 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 2)
SecondarySubject Incidence With Spotting - Trimester 3 (Safety Pop.)

Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 3
Reported as:
Count of participants · Participants
Subject Incidence With Spotting - Trimester 3 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Spotting - Trimester 3 (Safety Pop.)543329182
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 3)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 3)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.025 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 3)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.182 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 3)
SecondarySubject Incidence With Spotting - Trimester 4 (Safety Pop.)

Summary of subject incidence with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 4
Reported as:
Count of participants · Participants
Subject Incidence With Spotting - Trimester 4 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Spotting - Trimester 4 (Safety Pop.)472127184
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.002 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 4)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.469 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 4)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.188 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 4)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.613 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 4)
SecondaryNumber of Days With Spotting - Trimester 1 (Safety Pop.)

Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 1
Reported as:
Mean · Days
Number of Days With Spotting - Trimester 1 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Spotting - Trimester 1 (Safety Pop.)3.0 ± 8.811.7 ± 6.051.3 ± 5.080.8 ± 2.290.6 ± 2.63
SecondaryNumber of Days With Spotting - Trimester 2 (Safety Pop.)

Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 2
Reported as:
Mean · Days
Number of Days With Spotting - Trimester 2 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Spotting - Trimester 2 (Safety Pop.)2.9 ± 8.630.9 ± 3.851.5 ± 9.160.7 ± 4.300.1 ± 0.74
SecondaryNumber of Days With Spotting - Trimester 3 (Safety Pop.)

Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 3
Reported as:
Mean · Days
Number of Days With Spotting - Trimester 3 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Spotting - Trimester 3 (Safety Pop.)2.5 ± 8.280.7 ± 2.550.9 ± 6.040.3 ± 1.900.0 ± 0.14
SecondaryNumber of Days With Spotting - Trimester 4 (Safety Pop.)

Summary of the number of days with spotting per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 4
Reported as:
Mean · Days
Number of Days With Spotting - Trimester 4 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Spotting - Trimester 4 (Safety Pop.)1.9 ± 7.590.5 ± 3.360.8 ± 5.750.3 ± 1.170.1 ± 0.67
SecondarySubject Incidence With Bleeding - Trimester 1 (Safety Pop.)

Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 1
Reported as:
Count of participants · Participants
Subject Incidence With Bleeding - Trimester 1 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Bleeding - Trimester 1 (Safety Pop.)482925244
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.002 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 1)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.135 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 1)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.260 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 1)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.257 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 1)
SecondarySubject Incidence With Bleeding - Trimester 2 (Safety Pop.)

Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 2
Reported as:
Count of participants · Participants
Subject Incidence With Bleeding - Trimester 2 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Bleeding - Trimester 2 (Safety Pop.)45231952
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 2)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.085 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 2)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.184 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 2)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.681 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 2)
SecondarySubject Incidence With Bleeding - Trimester 3 (Safety Pop.)

Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 3
Reported as:
Count of participants · Participants
Subject Incidence With Bleeding - Trimester 3 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Bleeding - Trimester 3 (Safety Pop.)25211671
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.008 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 3)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.036 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 3)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.138 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 3)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 0.685 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 3)
SecondarySubject Incidence With Bleeding - Trimester 4 (Safety Pop.)

Summary of subject incidence with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 4
Reported as:
Count of participants · Participants
Subject Incidence With Bleeding - Trimester 4 (Safety Pop.)
ParticipantsCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Subject Incidence With Bleeding - Trimester 4 (Safety Pop.)2716952
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.023 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo during Trimester 4)
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Fisher Exact · p = 0.265 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo during Trimester 4)
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo during Trimester 4)
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Fisher Exact · p = 1.000 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo during Trimester 4)
SecondaryNumber of Days With Bleeding - Trimester 1 (Safety Pop.)

Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 1
Reported as:
Mean · Days
Number of Days With Bleeding - Trimester 1 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Bleeding - Trimester 1 (Safety Pop.)1.2 ± 5.220.5 ± 2.210.5 ± 2.240.4 ± 1.790.2 ± 1.01
SecondaryNumber of Days With Bleeding - Trimester 2 (Safety Pop.)

Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 2
Reported as:
Mean · Days
Number of Days With Bleeding - Trimester 2 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Bleeding - Trimester 2 (Safety Pop.)0.9 ± 3.220.4 ± 1.850.4 ± 2.020.2 ± 1.770.1 ± 0.42
SecondaryNumber of Days With Bleeding - Trimester 3 (Safety Pop.)

Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 3
Reported as:
Mean · Days
Number of Days With Bleeding - Trimester 3 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Bleeding - Trimester 3 (Safety Pop.)0.5 ± 2.320.5 ± 2.290.2 ± 1.430.1 ± 0.670.0 ± 0.10
SecondaryNumber of Days With Bleeding - Trimester 4 (Safety Pop.)

Summary of the number of days with bleeding per trimester as recorded in a daily diary. A trimester is defined as every 90 days since Day 1.

Time frame:
Trimester 4
Reported as:
Mean · Days
Number of Days With Bleeding - Trimester 4 (Safety Pop.)
DaysCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Number of Days With Bleeding - Trimester 4 (Safety Pop.)0.8 ± 3.480.4 ± 2.060.2 ± 1.200.0 ± 0.260.1 ± 0.43
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS)

Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · Score on a Scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS)
Score on a ScaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT-VMS)-3.8 ± 1.98-3.3 ± 2.04-3.3 ± 1.97-3.2 ± 2.13-2.2 ± 1.83
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.65 · 95% CI -2.13 to -1.17
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.31 · 95% CI -1.79 to -0.84
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -1.17 · 95% CI -1.64 to -0.69
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -1.04 · 95% CI -1.51 to -0.58
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS)

Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT-VMS)-4.3 ± 1.94-4.1 ± 1.99-4.0 ± 2.12-3.5 ± 1.95-3.0 ± 2.26
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.40 · 95% CI -1.91 to -0.89
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.32 · 95% CI -1.81 to -0.82
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -1.12 · 95% CI -1.63 to -0.62
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.69 · 95% CI -1.19 to -0.19
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS)

Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT-VMS)-4.0 ± 2.15-4.1 ± 1.77-4.0 ± 2.11-3.4 ± 1.75-2.8 ± 2.26
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -1.20 · 95% CI -1.75 to -0.66
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -1.46 · 95% CI -1.98 to -0.94
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -1.23 · 95% CI -1.76 to -0.69
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.008 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.72 · 95% CI -1.26 to -0.19
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS)

Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT-VMS)-1.1 ± 1.42-0.9 ± 1.56-1.2 ± 1.69-1.1 ± 1.36-1.0 ± 1.66
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.284 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.17 · 95% CI -0.49 to 0.14
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.732 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.05 · 95% CI -0.36 to 0.26
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.437 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.12 · 95% CI -0.44 to 0.19
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.439 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.12 · 95% CI -0.43 to 0.19
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS)

Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT-VMS)-1.3 ± 1.64-1.1 ± 1.44-1.1 ± 1.76-1.0 ± 1.57-1.0 ± 1.61
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.040 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.35 · 95% CI -0.68 to -0.02
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.066 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.30 · 95% CI -0.63 to 0.02
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.469 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.12 · 95% CI -0.45 to 0.21
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.616 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.08 · 95% CI -0.41 to 0.24
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS)

Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT-VMS)-1.1 ± 1.51-1.3 ± 1.61-1.1 ± 1.84-1.0 ± 1.67-1.0 ± 1.61
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.250 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.21 · 95% CI -0.57 to 0.15
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.54 · 95% CI -0.88 to -0.20
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.796 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.05 · 95% CI -0.40 to 0.31
  • Combined Estradiol 0.25 mg / Progesterone 50 mg · Mixed Models Analysis · p = 0.955 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.01 · 95% CI -0.36 to 0.34
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS)

Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT-VMS)-1.1 ± 1.30-1.0 ± 1.32-1.5 ± 1.50-1.0 ± 1.30-1.0 ± 1.38
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.474 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.10 · 95% CI -0.38 to 0.18
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.378 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.12 · 95% CI -0.40 to 0.15
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.018 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.33 · 95% CI -0.61 to -0.06
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.730 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.05 · 95% CI -0.32 to 0.22
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS)

Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT-VMS)-1.2 ± 1.32-1.1 ± 1.37-1.5 ± 1.61-1.0 ± 1.28-1.1 ± 1.40
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.197 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.20 · 95% CI -0.49 to 0.10
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.308 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.15 · 95% CI -0.44 to 0.14
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.117 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.24 · 95% CI -0.54 to 0.06
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.739 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.05 · 95% CI -0.34 to 0.24
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS)

Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT-VMS)-1.0 ± 1.57-1.2 ± 1.29-1.4 ± 1.60-1.1 ± 1.44-0.9 ± 1.39
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.635 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.08 · 95% CI -0.42 to 0.26
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.010 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.43 · 95% CI -0.75 to -0.10
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.092 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.28 · 95% CI -0.62 to 0.05
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.243 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.20 · 95% CI -0.53 to 0.13
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS)

Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT-VMS)-1.5 ± 2.03-1.1 ± 1.98-1.7 ± 2.04-1.4 ± 2.16-1.3 ± 2.22
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.049 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.41 · 95% CI -0.83 to -0.00
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.773 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 0.06 · 95% CI -0.34 to 0.46
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.081 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.36 · 95% CI -0.77 to 0.05
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.625 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.10 · 95% CI -0.50 to 0.30
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS)

Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT-VMS)-1.3 ± 2.18-1.2 ± 2.03-1.6 ± 2.12-1.4 ± 2.13-1.3 ± 1.93
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.221 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.27 · 95% CI -0.70 to 0.16
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.992 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.00 · 95% CI -0.42 to 0.42
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.181 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.29 · 95% CI -0.72 to 0.14
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.846 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.04 · 95% CI -0.47 to 0.38
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS)

Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT-VMS)-1.0 ± 2.44-1.5 ± 2.20-1.5 ± 2.26-1.4 ± 2.19-1.1 ± 2.29
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.421 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.21 · 95% CI -0.71 to 0.30
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.044 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.49 · 95% CI -0.97 to -0.01
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.093 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.42 · 95% CI -0.92 to 0.07
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.247 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.29 · 95% CI -0.79 to 0.20
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS)

Changes in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT-VMS)-1.9 ± 1.20-1.6 ± 1.23-1.9 ± 1.41-1.7 ± 1.31-1.4 ± 1.36
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.58 · 95% CI -0.87 to -0.29
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.016 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.34 · 95% CI -0.62 to -0.06
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.48 · 95% CI -0.76 to -0.20
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.023 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.32 · 95% CI -0.60 to -0.05
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS)

Changes in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT-VMS)-2.0 ± 1.22-1.8 ± 1.22-2.1 ± 1.50-1.7 ± 1.24-1.6 ± 1.31
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.55 · 95% CI -0.84 to -0.25
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.42 · 95% CI -0.71 to -0.13
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.44 · 95% CI -0.73 to -0.14
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.179 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.20 · 95% CI -0.49 to 0.09
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS)

Changes in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT-VMS)-1.8 ± 1.45-2.0 ± 1.27-2.0 ± 1.50-1.7 ± 1.29-1.5 ± 1.50
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.012 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.43 · 95% CI -0.76 to -0.10
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.73 · 95% CI -1.05 to -0.41
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.49 · 95% CI -0.81 to -0.16
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.070 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.30 · 95% CI -0.63 to 0.03
SecondaryMedical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS)

Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT-VMS)-16.7 ± 16.99-13.1 ± 16.22-18.5 ± 19.41-14.6 ± 18.80-11.5 ± 19.67
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.033 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -4.39 · 95% CI -8.44 to -0.35
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.207 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -2.54 · 95% CI -6.50 to 1.41
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.024 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -4.60 · 95% CI -8.58 to -0.61
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.207 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -2.53 · 95% CI -6.47 to 1.41
SecondaryMedical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS)

Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT-VMS)-17.8 ± 17.28-16.0 ± 16.60-19.8 ± 21.18-16.6 ± 19.01-11.7 ± 19.40
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.011 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.48 · 95% CI -9.68 to -1.28
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.012 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.25 · 95% CI -9.36 to -1.14
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.58 · 95% CI -9.75 to -1.41
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.018 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -4.99 · 95% CI -9.11 to -0.87
SecondaryMedical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS)

Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT-VMS)-14.9 ± 21.09-15.8 ± 17.72-20.6 ± 21.58-17.6 ± 18.81-10.3 ± 21.78
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.058 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -4.61 · 95% CI -9.38 to 0.16
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -7.48 · 95% CI -12.04 to -2.92
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -7.96 · 95% CI -12.67 to -3.25
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.78 · 95% CI -11.50 to -2.06
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS)

Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 (MITT-VMS)-22.3 ± 23.72-17.7 ± 24.75-23.6 ± 25.07-19.3 ± 26.31-15.1 ± 26.65
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.020 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -6.48 · 95% CI -11.92 to -1.04
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.216 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -3.36 · 95% CI -8.69 to 1.97
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.033 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -5.85 · 95% CI -11.22 to -0.48
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.265 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -2.99 · 95% CI -8.27 to 2.28
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS)

Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT-VMS)-23.5 ± 25.99-21.3 ± 24.42-26.9 ± 26.91-22.4 ± 26.76-15.4 ± 27.57
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.008 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -7.54 · 95% CI -13.14 to -1.93
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.016 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -6.72 · 95% CI -12.18 to -1.26
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -8.69 · 95% CI -14.28 to -3.10
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.028 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -6.18 · 95% CI -11.68 to -0.68
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS)

Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT-VMS)-20.0 ± 28.25-22.3 ± 24.84-26.1 ± 27.21-26.1 ± 25.32-14.1 ± 28.67
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.040 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -6.56 · 95% CI -12.80 to -0.31
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -10.02 · 95% CI -15.99 to -4.04
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -9.96 · 95% CI -16.11 to -3.81
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.029 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.85 · 95% CI -12.99 to -0.70
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS)

Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT-VMS)-0.5 ± 23.73-3.6 ± 25.84-7.1 ± 28.49-5.7 ± 24.65-5.7 ± 25.13
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.294 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 3.15 · 95% CI -2.75 to 9.05
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.327 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 2.86 · 95% CI -2.87 to 8.60
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.637 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -1.39 · 95% CI -7.18 to 4.39
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.952 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 0.17 · 95% CI -5.51 to 5.86
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS)

Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT-VMS)0.7 ± 26.29-5.5 ± 26.24-8.8 ± 24.47-6.1 ± 30.29-3.5 ± 27.08
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.573 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 1.82 · 95% CI -4.51 to 8.14
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.769 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.91 · 95% CI -7.01 to 5.19
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.047 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -6.33 · 95% CI -12.56 to -0.09
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.409 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -2.59 · 95% CI -8.74 to 3.56
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS)

Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT-VMS)-1.1 ± 28.04-10.5 ± 29.43-6.2 ± 27.03-8.0 ± 26.77-4.5 ± 26.23
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.579 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 1.91 · 95% CI -4.85 to 8.67
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.223 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -3.99 · 95% CI -10.43 to 2.44
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.542 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -2.05 · 95% CI -8.67 to 4.56
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.476 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -2.41 · 95% CI -9.04 to 4.23
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS)

Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT-VMS)-7.7 ± 26.83-4.3 ± 22.18-12.3 ± 29.62-7.9 ± 27.67-3.6 ± 25.52
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.631 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.25 · 95% CI -6.34 to 3.84
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.651 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 1.15 · 95% CI -3.84 to 6.14
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.813 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.61 · 95% CI -5.67 to 4.45
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.869 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.42 · 95% CI -5.35 to 4.52
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS)

Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT-VMS)-9.7 ± 27.72-5.0 ± 27.50-11.0 ± 33.55-7.3 ± 26.96-2.1 ± 23.47
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.074 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.00 · 95% CI -10.48 to 0.48
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.748 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.87 · 95% CI -6.22 to 4.47
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.987 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 0.05 · 95% CI -5.46 to 5.56
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.709 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -1.02 · 95% CI -6.41 to 4.36
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS)

Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT-VMS)-8.9 ± 30.41-7.1 ± 24.60-12.4 ± 34.65-10.8 ± 27.15-2.8 ± 27.60
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.379 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -2.61 · 95% CI -8.44 to 3.22
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.279 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -3.07 · 95% CI -8.64 to 2.49
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.894 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.39 · 95% CI -6.19 to 5.40
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.308 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -2.98 · 95% CI -8.72 to 2.76
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS)

Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT-VMS)12.8 ± 28.3011.0 ± 26.5717.3 ± 30.0610.7 ± 28.3311.3 ± 26.09
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.558 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 1.81 · 95% CI -4.24 to 7.86
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.233 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 3.61 · 95% CI -2.34 to 9.57
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.043 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 6.16 · 95% CI 0.20 to 12.13
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.488 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 2.07 · 95% CI -3.80 to 7.95
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS)

Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT-VMS)13.2 ± 28.6115.2 ± 26.8914.7 ± 30.1215.2 ± 28.759.5 ± 27.36
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.205 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 4.07 · 95% CI -2.23 to 10.37
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 9.58 · 95% CI 3.43 to 15.74
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.115 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 5.04 · 95% CI -1.23 to 11.32
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 8.94 · 95% CI 2.75 to 15.13
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS)

Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT-VMS)10.4 ± 28.4310.5 ± 31.0717.6 ± 31.6113.7 ± 27.7010.0 ± 31.76
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.796 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 0.96 · 95% CI -6.34 to 8.27
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.150 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 5.14 · 95% CI -1.87 to 12.15
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.019 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): 8.58 · 95% CI 1.39 to 15.77
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.041 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): 7.51 · 95% CI 0.30 to 14.71
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS)

Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT-VMS)-11.3 ± 20.70-9.2 ± 17.82-10.4 ± 22.61-10.8 ± 21.78-8.7 ± 20.62
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.221 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -2.69 · 95% CI -7.00 to 1.62
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.511 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.42 · 95% CI -5.65 to 2.81
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.761 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 0.66 · 95% CI -3.60 to 4.92
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.332 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -2.07 · 95% CI -6.25 to 2.11
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS)

Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT-VMS)-10.1 ± 21.60-10.8 ± 21.46-12.4 ± 22.98-10.5 ± 23.69-9.6 ± 21.64
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.687 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.00 · 95% CI -5.86 to 3.86
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.373 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -2.15 · 95% CI -6.88 to 2.58
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.714 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.91 · 95% CI -5.75 to 3.94
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.711 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.90 · 95% CI -5.67 to 3.87
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS)

Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT-VMS)-8.0 ± 22.93-11.1 ± 21.51-13.1 ± 20.03-13.4 ± 23.82-6.7 ± 25.95
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.415 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -2.19 · 95% CI -7.46 to 3.08
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.019 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -6.01 · 95% CI -11.04 to -0.97
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.074 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -4.72 · 95% CI -9.90 to 0.46
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.030 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -5.75 · 95% CI -10.94 to -0.57
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS)

Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT-VMS)-15.2 ± 17.45-11.3 ± 17.04-17.7 ± 19.47-13.5 ± 19.65-9.9 ± 20.50
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.059 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -3.99 · 95% CI -8.13 to 0.16
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.215 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -2.57 · 95% CI -6.63 to 1.49
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.015 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -5.10 · 95% CI -9.19 to -1.00
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.122 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -3.16 · 95% CI -7.17 to 0.85
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS)

Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT-VMS)-16.1 ± 16.64-14.3 ± 16.56-18.0 ± 20.71-15.7 ± 19.34-9.8 ± 20.37
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.013 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.32 · 95% CI -9.52 to -1.13
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.76 · 95% CI -9.85 to -1.68
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.59 · 95% CI -9.77 to -1.40
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.68 · 95% CI -9.79 to -1.57
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS)

Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT-VMS)-13.3 ± 20.52-13.5 ± 18.04-18.9 ± 21.49-16.1 ± 20.01-9.1 ± 22.62
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.171 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -3.39 · 95% CI -8.24 to 1.47
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -6.49 · 95% CI -11.14 to -1.85
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -7.39 · 95% CI -12.17 to -2.61
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.69 · 95% CI -11.46 to -1.92
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS)

Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT-VMS)-16.8 ± 17.14-13.1 ± 16.16-18.5 ± 19.34-14.4 ± 19.19-11.8 ± 19.56
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.039 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -4.21 · 95% CI -8.21 to -0.21
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.232 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -2.39 · 95% CI -6.31 to 1.53
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.030 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -4.37 · 95% CI -8.32 to -0.42
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.262 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -2.22 · 95% CI -6.09 to 1.66
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS)

Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 6 - (MITT-VMS)-17.5 ± 17.40-16.0 ± 16.69-19.8 ± 21.18-17.0 ± 19.02-11.6 ± 19.31
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.011 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.41 · 95% CI -9.57 to -1.25
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.008 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.54 · 95% CI -9.60 to -1.48
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.74 · 95% CI -9.90 to -1.59
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.011 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.32 · 95% CI -9.40 to -1.24
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS)

Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT-VMS)-14.7 ± 21.13-15.7 ± 17.65-20.5 ± 21.49-17.4 ± 19.48-10.5 ± 21.71
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.083 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -4.21 · 95% CI -8.96 to 0.55
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -7.36 · 95% CI -11.91 to -2.81
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -7.92 · 95% CI -12.60 to -3.23
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.005 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.78 · 95% CI -11.46 to -2.10
SecondaryMedical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS)

Change from Baseline (BL) to Week 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

Time frame:
Baseline and Week 12
Reported as:
Mean · Proportion of Net Change
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS)
Proportion of Net ChangeCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT-VMS)0.2 ± 0.550.2 ± 0.540.2 ± 0.450.2 ± 0.530.2 ± 0.58
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.938 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.00 · 95% CI -0.12 to 0.11
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.779 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 0.02 · 95% CI -0.10 to 0.13
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.646 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.03 · 95% CI -0.14 to 0.09
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.421 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 0.05 · 95% CI -0.07 to 0.16
SecondaryMedical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS)

Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

Time frame:
Baseline and Month 6
Reported as:
Mean · Proportion of Net Change
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS)
Proportion of Net ChangeCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT-VMS)0.3 ± 0.520.2 ± 0.520.2 ± 0.570.1 ± 0.570.2 ± 0.52
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.075 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 0.11 · 95% CI -0.01 to 0.24
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.074 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 0.11 · 95% CI -0.01 to 0.23
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.370 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 0.06 · 95% CI -0.07 to 0.18
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.851 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 0.01 · 95% CI -0.11 to 0.13
SecondaryMedical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS)

Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

Time frame:
Baseline and Month 12
Reported as:
Mean · Proportion of Net Change
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS)
Proportion of Net ChangeCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT-VMS)0.2 ± 0.470.3 ± 0.580.1 ± 0.570.1 ± 0.510.2 ± 0.47
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.452 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.05 · 95% CI -0.18 to 0.08
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.244 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 0.07 · 95% CI -0.05 to 0.20
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.354 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.06 · 95% CI -0.19 to 0.07
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.527 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.04 · 95% CI -0.17 to 0.09
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT)

Changes in Vasomotor Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Week 12 (MITT)-3.5 ± 2.02-3.1 ± 2.00-3.1 ± 2.01-2.9 ± 1.94-2.2 ± 1.84
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.92 · 95% CI -2.29 to -1.55
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.44 · 95% CI -1.81 to -1.07
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -1.44 · 95% CI -1.81 to -1.07
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -1.25 · 95% CI -1.62 to -0.88
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT)

Changes in Vasomotor Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 6 (MITT)-4.0 ± 1.95-3.7 ± 2.02-3.5 ± 2.15-3.3 ± 1.94-3.0 ± 2.26
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.73 · 95% CI -2.12 to -1.34
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.29 · 95% CI -1.68 to -0.91
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -1.20 · 95% CI -1.58 to -0.81
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.96 · 95% CI -1.34 to -0.57
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT)

Changes in Vasomotor Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Vasomotor domain score is mean of = Q1,Q2, Q3, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Vasomotor Domain Score - Month 12 (MITT)-3.8 ± 2.05-3.7 ± 1.89-3.4 ± 2.06-3.3 ± 1.80-2.8 ± 2.26
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -1.65 · 95% CI -2.06 to -1.25
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -1.47 · 95% CI -1.87 to -1.07
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -1.30 · 95% CI -1.70 to -0.90
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -1.08 · 95% CI -1.48 to -0.67
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT)

Changes in Psychosocial Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Week 12 (MITT)-1.1 ± 1.52-1.0 ± 1.66-1.1 ± 1.58-1.0 ± 1.49-1.0 ± 1.68
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.126 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.20 · 95% CI -0.46 to 0.06
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.200 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.17 · 95% CI -0.42 to 0.09
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.222 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.16 · 95% CI -0.41 to 0.10
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.358 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.12 · 95% CI -0.37 to 0.14
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT)

Changes in Psychosocial Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 6 (MITT)-1.3 ± 1.68-1.1 ± 1.65-1.1 ± 1.65-1.0 ± 1.55-1.0 ± 1.61
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.023 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.31 · 95% CI -0.59 to -0.04
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.045 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.28 · 95% CI -0.55 to -0.01
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.384 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.12 · 95% CI -0.39 to 0.15
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.424 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.11 · 95% CI -0.38 to 0.16
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT)

Changes in Psychosocial Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Psychosocial domain score is mean of = Q4 to Q10, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Psychosocial Domain Score - Month 12 (MITT)-1.1 ± 1.65-1.1 ± 1.74-1.1 ± 1.66-1.0 ± 1.64-1.0 ± 1.61
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.153 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.22 · 95% CI -0.52 to 0.08
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.058 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.29 · 95% CI -0.58 to 0.01
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.550 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.09 · 95% CI -0.39 to 0.21
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.854 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.03 · 95% CI -0.33 to 0.27
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT)

Changes in Physical Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Week 12 (MITT)-1.1 ± 1.41-1.1 ± 1.44-1.3 ± 1.40-1.1 ± 1.39-1.0 ± 1.38
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.181 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.16 · 95% CI -0.38 to 0.07
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.108 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.19 · 95% CI -0.41 to 0.04
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.014 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.28 · 95% CI -0.51 to -0.06
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.323 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.11 · 95% CI -0.34 to 0.11
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT)

Changes in Physical Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 6 (MITT)-1.2 ± 1.42-1.1 ± 1.46-1.2 ± 1.46-1.0 ± 1.39-1.1 ± 1.40
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.056 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.24 · 95% CI -0.48 to 0.01
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.279 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.13 · 95% CI -0.38 to 0.11
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.435 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.10 · 95% CI -0.34 to 0.15
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.607 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.06 · 95% CI -0.31 to 0.18
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT)

Changes in Physical Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Physical domain score is mean of = Q11 to Q26, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Physical Domain Score - Month 12 (MITT)-1.1 ± 1.52-1.1 ± 1.48-1.2 ± 1.43-1.1 ± 1.50-0.9 ± 1.39
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.060 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.26 · 95% CI -0.53 to 0.01
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.026 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.30 · 95% CI -0.57 to -0.04
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.097 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.23 · 95% CI -0.49 to 0.04
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.230 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.17 · 95% CI -0.44 to 0.10
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT)

Changes in Sexual Domain Score from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Week 12 (MITT)-1.4 ± 2.06-1.3 ± 2.21-1.5 ± 2.02-1.5 ± 2.15-1.3 ± 2.21
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.107 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.27 · 95% CI -0.61 to 0.06
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.302 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.17 · 95% CI -0.51 to 0.16
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.106 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.27 · 95% CI -0.60 to 0.06
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.156 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.24 · 95% CI -0.57 to 0.09
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT)

Changes in Sexual Domain Score from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 6 (MITT)-1.4 ± 2.11-1.4 ± 2.12-1.4 ± 2.05-1.3 ± 2.10-1.3 ± 1.93
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.081 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.31 · 95% CI -0.65 to 0.04
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.212 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.22 · 95% CI -0.56 to 0.12
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.345 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.17 · 95% CI -0.51 to 0.18
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.829 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.04 · 95% CI -0.38 to 0.31
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT)

Changes in Sexual Domain Score from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The scale contains four domains: vasomotor, psychosocial, physical and sexual. Each domain is scored separately. Sexual domain score is mean of = Q27 to Q29, with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Sexual Domain Score - Month 12 (MITT)-1.3 ± 2.26-1.4 ± 2.32-1.3 ± 2.10-1.2 ± 2.25-1.1 ± 2.29
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.029 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.44 · 95% CI -0.84 to -0.05
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.026 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.45 · 95% CI -0.84 to -0.05
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.093 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.33 · 95% CI -0.72 to 0.06
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.223 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.25 · 95% CI -0.64 to 0.15
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT)

Change in Overall Scores from Baseline to Week 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Week 12 (MITT)-1.8 ± 1.31-1.6 ± 1.38-1.7 ± 1.35-1.6 ± 1.35-1.4 ± 1.36
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.62 · 95% CI -0.85 to -0.40
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.49 · 95% CI -0.71 to -0.26
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.52 · 95% CI -0.75 to -0.30
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.42 · 95% CI -0.64 to -0.20
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT)

Change in Overall Scores from Baseline to Month 6. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 6 (MITT)-2.0 ± 1.32-1.8 ± 1.38-1.8 ± 1.39-1.7 ± 1.29-1.6 ± 1.31
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.61 · 95% CI -0.85 to -0.38
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -0.45 · 95% CI -0.69 to -0.22
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.36 · 95% CI -0.59 to -0.12
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.030 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.26 · 95% CI -0.50 to -0.03
SecondaryMenopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT)

Change in Overall Scores from Baseline to Month 12. The MENQOL is self-administered questionnaire which assessed changes in quality of life over a one-month period. It is composed of 29 questions indicating if subject experienced the problem (Yes/No) and if Yes, rating scale ranged from 0=Not bothered at all to 6=Extremely bothered. The scale contains four domains: vasomotor, psychosocial, physical and sexual. For analysis, the original scores were converted to the analysis score ranging from 1-8 where No=1, 0=2, 1=3...and 6=8. The Overall Score is the mean of the 4 domain scores with 1 being "not at all bothered" and 8 being "extremely bothered".

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Menopause-specific Quality of Life Questionnaire (MENQOL) - Overall Scores - Month 12 (MITT)-1.8 ± 1.43-1.8 ± 1.45-1.7 ± 1.38-1.6 ± 1.38-1.5 ± 1.50
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.62 · 95% CI -0.89 to -0.36
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.62 · 95% CI -0.88 to -0.36
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.47 · 95% CI -0.73 to -0.21
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.37 · 95% CI -0.63 to -0.10
SecondaryMedical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT)

Change from Baseline to Wk 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Week 12 (MITT)-15.1 ± 17.64-13.0 ± 17.42-13.9 ± 17.40-13.3 ± 18.22-11.5 ± 19.60
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -4.88 · 95% CI -8.08 to -1.69
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.027 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -3.61 · 95% CI -6.80 to -0.42
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.034 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -3.44 · 95% CI -6.61 to -0.26
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.119 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -2.53 · 95% CI -5.71 to 0.65
SecondaryMedical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT)

Change from Baseline to Month 6 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 6 (MITT)-15.6 ± 18.13-14.8 ± 16.10-14.7 ± 18.95-14.6 ± 18.93-11.7 ± 19.40
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.39 · 95% CI -8.73 to -2.05
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.39 · 95% CI -8.72 to -2.06
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.004 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -4.88 · 95% CI -8.19 to -1.58
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -4.42 · 95% CI -7.75 to -1.09
SecondaryMedical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT)

Change from Baseline to Month 12 in MOS Total Sleep Score as compared w/Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Total score includes items Q1, 3, 4, 5, 6, 7, 8, 9, \& 12. Scoring method: Answers to Q3, 5, 6, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q1, 4, \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Total score= average of item scores; ranges =0 to 100, where higher score means worse outcome. If any of individual questions used to obtain total score is missing, total score will be set to missing value.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Sleep Scale - Total Sleep Score - Month 12 (MITT)-14.4 ± 18.36-14.5 ± 17.85-15.3 ± 18.78-15.3 ± 19.28-10.3 ± 21.78
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -6.54 · 95% CI -10.18 to -2.90
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -7.61 · 95% CI -11.23 to -4.00
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -7.44 · 95% CI -11.04 to -3.84
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.76 · 95% CI -10.41 to -3.10
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT)

Change from Baseline to Wk 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Week 12 - (MITT)-21.0 ± 23.74-18.1 ± 24.62-18.7 ± 23.11-17.3 ± 24.88-14.9 ± 26.57
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -7.34 · 95% CI -11.55 to -3.13
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -5.60 · 95% CI -9.80 to -1.40
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.016 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -5.13 · 95% CI -9.31 to -0.95
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.154 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -3.04 · 95% CI -7.22 to 1.14
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT)

Change from Baseline to Month 6 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 6 - (MITT)-22.3 ± 25.24-20.2 ± 22.46-20.1 ± 25.12-19.4 ± 24.85-15.4 ± 27.57
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -8.38 · 95% CI -12.72 to -4.04
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -7.52 · 95% CI -11.83 to -3.20
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -7.32 · 95% CI -11.63 to -3.02
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.011 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.60 · 95% CI -9.93 to -1.27
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT)

Change from Baseline to Month 12 in MOS Sleep Disturbance individual score as compared with Placebo. MOS-Sleep Self Report Questionnaire is 12 items that measure 6 dimensions of sleep over past 4 wks. Q1 scored on scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 self-reported hrs of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep disturbance includes items Q1, Q3, Q7, Q8. Scoring method: Answer to Q1 is rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25. Answers to Q3, 7, 8 are reversed \& rescaled to realign to be same direction and range(0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Score is average of item scores; score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Disturbance - Month 12 - (MITT)-20.2 ± 25.27-19.9 ± 24.90-19.9 ± 25.01-19.7 ± 24.13-14.1 ± 28.67
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -8.97 · 95% CI -13.76 to -4.19
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -9.60 · 95% CI -14.34 to -4.85
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -9.30 · 95% CI -14.03 to -4.56
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -7.72 · 95% CI -12.51 to -2.93
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT)

Change from Baseline to Wk 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Week 12 - (MITT)-2.6 ± 25.30-4.7 ± 26.08-4.5 ± 28.93-3.4 ± 26.94-5.6 ± 25.03
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.434 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 2.02 · 95% CI -3.03 to 7.07
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.442 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 1.97 · 95% CI -3.06 to 7.00
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.558 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 1.50 · 95% CI -3.52 to 6.51
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.534 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 1.59 · 95% CI -3.42 to 6.60
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT)

Change from Baseline to Month 6 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 6 - (MITT)-2.4 ± 28.00-6.0 ± 25.73-6.8 ± 27.32-3.7 ± 28.98-3.5 ± 27.08
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.927 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 0.25 · 95% CI -5.08 to 5.58
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.541 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.65 · 95% CI -6.95 to 3.64
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.171 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -3.68 · 95% CI -8.96 to 1.60
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.667 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -1.17 · 95% CI -6.48 to 4.15
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT)

Change from Baseline to Month 12 in MOS Snoring individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Snoring item is Q10. Scoring method: Answer to Q10 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Snoring - Month 12 - (MITT)-3.4 ± 29.62-7.5 ± 27.71-5.0 ± 28.57-4.5 ± 24.79-4.5 ± 26.23
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.662 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 1.25 · 95% CI -4.36 to 6.87
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.635 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -1.35 · 95% CI -6.91 to 4.21
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.877 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.44 · 95% CI -5.98 to 5.11
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.893 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.39 · 95% CI -6.01 to 5.24
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT)

Change from Baseline to Wk 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Week 12 - (MITT)-6.0 ± 24.56-6.0 ± 23.67-7.1 ± 27.97-6.3 ± 27.03-3.4 ± 25.50
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.830 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.44 · 95% CI -4.48 to 3.59
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.755 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -0.64 · 95% CI -4.66 to 3.38
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.802 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 0.51 · 95% CI -3.50 to 4.53
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.823 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.46 · 95% CI -4.46 to 3.55
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT)

Change from Baseline to Month 6 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 6 - (MITT)-6.2 ± 28.14-5.9 ± 24.36-7.5 ± 27.19-5.7 ± 26.34-2.1 ± 23.47
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.255 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -2.46 · 95% CI -6.71 to 1.78
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.293 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -2.27 · 95% CI -6.49 to 1.96
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.502 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -1.44 · 95% CI -5.66 to 2.77
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.495 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -1.47 · 95% CI -5.71 to 2.76
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT)

Change from Baseline to Month 12 in MOS Sleep Short of Breath or Headache(SOBHA) individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. SOBHA item is Q5. Scoring method: Answer to Q5 is reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Short of Breath or Headache - Month 12 - (MITT)-6.6 ± 27.64-6.4 ± 23.58-7.9 ± 28.34-6.5 ± 28.07-2.8 ± 27.60
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.389 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -1.96 · 95% CI -6.42 to 2.50
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.281 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -2.43 · 95% CI -6.85 to 1.99
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.504 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -1.51 · 95% CI -5.92 to 2.91
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.460 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -1.68 · 95% CI -6.15 to 2.78
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT)

Change from Baseline to Wk 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Week 12 - (MITT)11.9 ± 29.129.0 ± 27.4011.4 ± 27.5411.9 ± 27.3011.3 ± 25.98
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.084 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 4.35 · 95% CI -0.58 to 9.28
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.298 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 2.61 · 95% CI -2.30 to 7.53
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.136 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 3.72 · 95% CI -1.17 to 8.62
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.163 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 3.48 · 95% CI -1.41 to 8.37
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT)

Change from Baseline to Month 6 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 6 - (MITT)10.5 ± 26.8611.7 ± 28.1111.0 ± 28.8514.5 ± 27.929.5 ± 27.36
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.054 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 5.11 · 95% CI -0.08 to 10.31
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 7.10 · 95% CI 1.93 to 12.26
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.025 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 5.90 · 95% CI 0.75 to 11.04
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 8.38 · 95% CI 3.20 to 13.55
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT)

Change from Baseline to Month 12 in MOS Sleep Adequacy individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Adequacy includes items Q4, Q12. Scoring method: Answers for Q4 and Q12 are reversed and rescaled to 0-100 as follows: MOS_4_new = (6-MOS_4_old) x 20; MOS_12_new = (6-MOS_12_old) x 20. Score is the average of item scores; score range = 0 to 100, where higher score means better outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Adequacy - Month 12 - (MITT)9.8 ± 27.3312.0 ± 29.8612.6 ± 27.7114.1 ± 28.8110.0 ± 31.76
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.089 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 5.02 · 95% CI -0.76 to 10.80
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.010 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 7.56 · 95% CI 1.83 to 13.29
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.009 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): 7.65 · 95% CI 1.94 to 13.36
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.007 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): 7.89 · 95% CI 2.11 to 13.67
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT)

Change from Baseline to Wk 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Week 12 - (MITT)-9.2 ± 20.49-8.1 ± 18.67-7.6 ± 19.57-8.9 ± 21.09-8.7 ± 20.54
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.349 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.64 · 95% CI -5.07 to 1.79
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.499 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -1.18 · 95% CI -4.60 to 2.24
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.936 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 0.14 · 95% CI -3.27 to 3.55
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.696 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.68 · 95% CI -4.08 to 2.72
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT)

Change from Baseline to Month 6 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 6 - (MITT)-9.4 ± 22.40-8.4 ± 19.88-9.6 ± 20.04-8.7 ± 21.65-9.6 ± 21.64
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.572 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.09 · 95% CI -4.86 to 2.69
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.553 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -1.14 · 95% CI -4.89 to 2.62
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.456 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -1.42 · 95% CI -5.16 to 2.32
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.949 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -0.12 · 95% CI -3.89 to 3.64
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT)

Change from Baseline to Month 12 in MOS Sleep Somnolence individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-Q12 are scored 1-6 ranging from 1=All of the time to 6=None of the time. Sleep Somnolence items include Q6, Q9, Q11. Scoring method: Answers to Q6, Q 9 and Q11 are reversed \& rescaled to 0 to 100 such that 0="best possible" \& 100="worst possible". MOS_n_new \<- (6-MOS_n_old) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Somnolence - Month 12 - (MITT)-8.5 ± 22.79-9.2 ± 19.17-9.9 ± 19.33-9.4 ± 23.06-6.7 ± 25.95
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.097 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -3.36 · 95% CI -7.34 to 0.61
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.008 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -5.34 · 95% CI -9.28 to -1.40
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.014 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -4.94 · 95% CI -8.87 to -1.01
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.056 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -3.88 · 95% CI -7.86 to 0.10
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT)

Change from Baseline to Wk 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Week 12 - (MITT)-13.5 ± 17.90-11.4 ± 18.02-12.2 ± 18.29-12.8 ± 19.33-9.8 ± 20.47
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -4.92 · 95% CI -8.18 to -1.65
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.023 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -3.79 · 95% CI -7.05 to -0.53
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.047 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -3.28 · 95% CI -6.52 to -0.04
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.039 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -3.41 · 95% CI -6.65 to -0.17
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT)

Change from Baseline to Month 6 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 6 - (MITT)-14.0 ± 17.60-12.9 ± 16.76-13.2 ± 19.16-13.8 ± 19.77-9.8 ± 20.37
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.69 · 95% CI -9.05 to -2.33
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.58 · 95% CI -8.93 to -2.24
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.12 · 95% CI -8.45 to -1.79
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.003 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.11 · 95% CI -8.46 to -1.76
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT)

Change from Baseline to Month 12 in MOS Sleep Problems Index I individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self-reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index I includes items Q4, Q5, Q7, Q8, Q9, Q12. Scoring method: Answers to Q, 5, 7, 8, 9 are reversed \& rescaled to realign to be same direction and range (0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20. Answers to Q4, \& 12 are rescaled to 0-100 as follows: MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index I - Month 12 - (MITT)-12.8 ± 18.19-13.0 ± 18.36-13.7 ± 19.02-14.0 ± 20.14-9.1 ± 22.62
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -6.01 · 95% CI -9.71 to -2.32
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -7.22 · 95% CI -10.89 to -3.55
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.92 · 95% CI -10.58 to -3.27
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.42 · 95% CI -10.12 to -2.72
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT)

Change from Baseline to Wk 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Week 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Week 12 - (MITT)-15.1 ± 17.64-13.0 ± 17.38-13.9 ± 17.40-13.4 ± 18.47-11.8 ± 19.48
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.004 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -4.60 · 95% CI -7.75 to -1.44
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.030 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): -3.49 · 95% CI -6.64 to -0.34
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.049 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -3.15 · 95% CI -6.29 to -0.02
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.121 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -2.48 · 95% CI -5.61 to 0.65
SecondaryMedical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT)

Change from Baseline to Month 6 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 6
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Sleep Problems Index II - Month 6 - (MITT)-15.5 ± 18.15-14.6 ± 16.41-14.9 ± 18.95-14.8 ± 18.87-11.6 ± 19.31
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.44 · 95% CI -8.74 to -2.14
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): -5.53 · 95% CI -8.81 to -2.25
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.002 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -5.12 · 95% CI -8.39 to -1.85
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.006 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): -4.64 · 95% CI -7.93 to -1.35
SecondaryMedical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT)

Change from Baseline to Month 12 in MOS Sleep Problems Index II individual score as compared with Placebo. The MOS-Sleep Self Report Questionnaire is composed of 12 items that measure 6 dimensions of sleep over the past 4 weeks. Q1 is scored on a scale 1-5: 1=0-15 min, 2=16-30 min...5=\>60 mins. Q2 is self reported hours of sleep per night. Q3-12 scored 1-6 where 1=All of the time to 6=None of the time. Sleep Problems Index II items include Q1, Q3, Q4, Q5, Q6, Q7, Q8, Q9, Q12. Scoring method: Answers to Q3, 5, 6, 7, 8, \& 9 are reversed \& rescaled to realign to be same direction and range 0 to 100 with 0="best possible" \& 100="worst possible" as follows: MOS_n_new = (6-MOS_n_old) x 20, for n=Q3, 5, 6, 7, 8, and 9. Answers to Q1, 4 \& 12 are rescaled to 0-100 as follows: MOS_1_new =(MOS_1_old - 1) x 25; MOS_4_new =(MOS_4_old - 1) x 20; MOS_12_new=(MOS_12_old - 1) x 20. Score is the average of item scores; score range range=0 to 100, where higher score means worse outcome.

Time frame:
Baseline and Month 12
Reported as:
Mean · score on a scale
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT)
score on a scaleCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Individual Score for Sleep Problems Index II - Month 12 - (MITT)-14.3 ± 18.35-14.6 ± 17.95-15.4 ± 18.74-15.1 ± 19.43-10.5 ± 21.71
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -6.28 · 95% CI -9.91 to -2.65
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -7.58 · 95% CI -11.18 to -3.98
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -7.43 · 95% CI -11.02 to -3.84
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = <0.001 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -6.54 · 95% CI -10.17 to -2.91
SecondaryMedical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT)

Change from Baseline (BL) to Wk 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

Time frame:
Baseline and Week 12
Reported as:
Mean · Proportion of Net Change
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT)
Proportion of Net ChangeCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Week 12 - (MITT)0.2 ± 0.530.1 ± 0.560.2 ± 0.490.1 ± 0.520.2 ± 0.59
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.225 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 0.06 · 95% CI -0.04 to 0.16
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.741 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Week 12) · Mean difference (final values): 0.02 · 95% CI -0.08 to 0.11
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.414 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): 0.04 · 95% CI -0.06 to 0.14
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.690 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Week 12) · Mean difference (final values): -0.02 · 95% CI -0.11 to 0.08
SecondaryMedical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT)

Change from Baseline (BL) to Month 6 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

Time frame:
Baseline and Month 6
Reported as:
Mean · Proportion of Net Change
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT)
Proportion of Net ChangeCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 6 - (MITT)0.2 ± 0.560.2 ± 0.550.2 ± 0.530.1 ± 0.560.2 ± 0.52
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.045 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 0.11 · 95% CI 0.00 to 0.21
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.069 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 6) · Mean difference (final values): 0.09 · 95% CI -0.01 to 0.20
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.126 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 0.08 · 95% CI -0.02 to 0.18
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.907 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 6) · Mean difference (final values): 0.01 · 95% CI -0.10 to 0.11
SecondaryMedical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT)

Change from Baseline (BL) to Month 12 in MOS Optimal Sleep Score as compared with Placebo.The MOS-Sleep Self Report Questionnaire is composed of 12 items measuring 6 dimensions of sleep over the past 4 wks. Optimal sleep is based on Q2 (self-reported average hrs sleep per night in past 4 wks). Scoring method: hrs of sleep coded 0 (non-optimal) or 1 (optimal) where 1-6 hrs \& 9-23 hrs = 0, 7-8 hrs = 1. Change from BL: subject sleeps 7-8 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = -1; subject sleeps 1-6 or 9-23 hrs at BL \& 7-8 hrs at follow-up, change = +1; subject sleeps 1-6 or 9-23 hrs at BL \& 1-6 or 9-23 hrs at follow-up, change = 0. Mean change from BL: changes are summed to give the Net Total (equivalent to the number subjects w/ improved sleep hrs minus the number subjects w/ worsened sleep hrs), which is divided by the number of subjects to give the mean proportion of net change, where \>0 = overall improvement and \<0 = overall worsening in the study arm.

Time frame:
Baseline and Month 12
Reported as:
Mean · Proportion of Net Change
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT)
Proportion of Net ChangeCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Medical Outcomes Sleep Study (MOS) Optimal Sleep - Month 12 - (MITT)0.1 ± 0.510.2 ± 0.560.1 ± 0.550.1 ± 0.520.2 ± 0.47
Statistical analysis
  • Combined Estradiol 1 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.992 (p-value is derived from comparison between Combined Estradiol 1 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): -0.00 · 95% CI -0.11 to 0.11
  • Combined Estradiol 0.5 mg / Progesterone 100 mg vs Placebo · Mixed Models Analysis · p = 0.450 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 100 mg against Placebo at Month 12) · Mean difference (final values): 0.04 · 95% CI -0.07 to 0.15
  • Combined Estradiol 0.5 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.663 (p-value is derived from comparison between Combined Estradiol 0.5 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.02 · 95% CI -0.13 to 0.08
  • Combined Estradiol 0.25 mg / Progesterone 50 mg vs Placebo · Mixed Models Analysis · p = 0.309 (p-value is derived from comparison between Combined Estradiol 0.25 mg / Progesterone 50 mg against Placebo at Month 12) · Mean difference (final values): -0.06 · 95% CI -0.16 to 0.05

Adverse events

Collected over Adverse Event data were collected on or after the subject signed Informed Consent through fifteen days following the last dose of Investigational Product. Treatment Emergent Adverse Event data were collected on or after the first dose of IP through fifteen days following the last dose of IP.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Combined Estradiol 1 mg / Progesterone 100 mg0/415 (0%)9/415 (2.2%)324/415 (78.1%)
Combined Estradiol 0.5 mg / Progesterone 100 mg0/424 (0%)15/424 (3.5%)277/424 (65.3%)
Combined Estradiol 0.5 mg / Progesterone 50 mg1/421 (0.2%)9/421 (2.1%)291/421 (69.1%)
Combined Estradiol 0.25 mg / Progesterone 50 mg0/424 (0%)11/424 (2.6%)232/424 (54.7%)
Placebo0/151 (0%)2/151 (1.3%)41/151 (27.2%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Cholecystitis InfectiveInfections and infestations0/4150/4240/4210/4241/151
Uterine ProlapseReproductive system and breast disorders0/4150/4240/4210/4241/151
DiverticulitisInfections and infestations2/4150/4240/4210/4240/151
Breast Cancer FemaleNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/4151/4240/4210/4240/151
PneumoniaInfections and infestations0/4152/4240/4210/4240/151
Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders0/4150/4240/4212/4240/151
Coronary Artery DiseaseCardiac disorders1/4150/4240/4210/4240/151
Colitis IschaemicGastrointestinal disorders1/4150/4240/4210/4240/151
Pancreatitis AcuteGastrointestinal disorders1/4150/4240/4210/4240/151
Gastroenteritis ViralInfections and infestations1/4150/4240/4210/4240/151
Most frequent other events
Showing 10 of 17
Most frequent other events
EventCombined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlacebo
Breast TendernessReproductive system and breast disorders45/41519/42425/42110/4241/151
HeadacheNervous system disorders31/41524/42445/42143/4244/151
NasopharyngitisInfections and infestations25/41541/42437/42124/4244/151
Upper Respiratory Tract InfectionInfections and infestations22/41526/42434/42115/4246/151
NauseaGastrointestinal disorders20/41525/42419/42116/4242/151
Back PainMusculoskeletal and connective tissue disorders22/41511/42415/42115/4241/151
Abdominal PainGastrointestinal disorders22/41510/42414/42115/4244/151
SinusitisInfections and infestations20/41515/42413/42113/4243/151
DizzinessNervous system disorders17/41515/42410/4218/4243/151
Pelvic PainReproductive system and breast disorders17/41515/42410/4217/4240/151

Baseline characteristics

Safety population

Age, Categorical
Age, Categorical(Participants)Combined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlaceboTotal
<=18 years000000
Between 18 and 65 years4154244214241511835
>=65 years000000
Age, Continuous
Age, Continuous(years)Combined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlaceboTotal
Mean54.7 ± 4.3754.5 ± 4.5254.9 ± 4.2754.4 ± 4.0454.5 ± 4.3254.6 ± 4.31
Sex: Female, Male
Sex: Female, Male(Participants)Combined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlaceboTotal
Female4154244214241511835
Male000000
Region of Enrollment
Region of Enrollment(participants)Combined Estradiol 1 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 100 mgCombined Estradiol 0.5 mg / Progesterone 50 mgCombined Estradiol 0.25 mg / Progesterone 50 mgPlaceboTotal
United States4154244214241511835
08

Study locations

119 sites
  • Simon Williamson Clinic
    Birmingham, Alabama 35211, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Coastal Clinical Research
    Mobile, Alabama 36608, United States
  • Mobile Ob-Gyn, P.C.
    Mobile, Alabama 36608, United States
  • Montgomery Women's Health
    Montgomery, Alabama 36117, United States
  • Advanced Research Associates
    Glendale, Arizona 85308, United States
  • Cactus Clinical Research
    Mesa, Arizona 85209, United States
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • Radiant Research (Tucson)
    Tucson, Arizona 85712, United States
  • Visions Clinical Research Tucson
    Tucson, Arizona 85712, United States
  • Health Star Research, LLC
    Hot Springs, Arkansas 71913, United States
  • Sutter East Bay Medical Foundation
    Berkeley, California 94705, United States
  • Grossmont Center for Clinical Research
    La Mesa, California 91942, United States
  • Futura Research
    Norwalk, California 90650, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Women's Health Care Research Corp.
    San Diego, California 92111, United States
  • Radiant Research, Inc.
    Santa Rosa, California 95405, United States
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Downtown Women's Healthcare
    Denver, Colorado 80209, United States
  • Horizon's Clinical Research Center
    Denver, Colorado 80220, United States
  • Red Rocks OB/Gyn
    Lakewood, Colorado 80228, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • Coastal Connecticut Research
    New London, Connecticut 06320, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Nature Coast Clinical Research
    Crystal River, Florida 34429, United States
  • Clinical Physiology Associates
    Fort Myers, Florida 33916, United States
  • Southeastern Integrated Medical, PL, d/b/a Florida Medical Research
    Gainesville, Florida 32607, United States
  • UF College of Medicine-Jacksonville, Dept. of Obstetrics and Gynecology
    Jacksonville, Florida 32207, United States
  • Suncoast Research
    Margate, Florida 33063, United States
  • Accelovance
    Melbourne, Florida 32934, United States
  • Suncoast Clinical Research, Inc
    New Port Richey, Florida 34652, United States
  • Ideal Clinical Research
    North Miami Beach, Florida 33162, United States
  • Segal Institute
    North Miami, Florida 33161, United States
  • Compass Research
    Orlando, Florida 32806, United States
  • Radiant Research (St. Petersburg)
    Pinellas Park, Florida 33781, United States
  • All Women's Healthcare of West Broward Discovery Clinical Research
    Plantation, Florida 33324, United States
  • Comprehensive Clinical Trials
    West Palm Beach, Florida 33409, United States
  • Radiant Research (Atlanta)
    Atlanta, Georgia 30328, United States
  • Women's Health Associates
    Atlanta, Georgia 30342, United States
  • Soapstone Center for Clinical Research
    Decatur, Georgia 30034, United States
  • Wake Research - Mount Vernon Clinical Research
    Sandy Springs, Georgia 30328, United States
  • Fellows Research Alliance
    Savannah, Georgia 31406, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Advanced Clinical Research
    Meridian, Idaho 83642, United States
  • Biofortis
    Addison, Illinois 60101, United States
  • Women's Health Practice
    Champaign, Illinois 61820, United States
  • Radiant Research (Chicago)
    Chicago, Illinois 60654, United States
  • The South Bend Clinic Granger
    Granger, Indiana 46530, United States
  • Davis Clinic
    Indianapolis, Indiana 46250, United States
  • Cypress Medical Research Center, LLC
    Wichita, Kansas 67226, United States
  • Central Kentucky Research Associates
    Lexington, Kentucky 40509, United States
  • Bluegrass Clinical Research
    Louisville, Kentucky 40291, United States
  • Horizon Research Group
    Eunice, Louisiana 70535, United States
  • Maryland Center for Sexual Health
    Lutherville, Maryland 21093, United States
  • Quest Research Institute
    Bingham Farms, Michigan 48025, United States
  • Female Pelvic Medicine & Urogynecology
    Grand Rapids, Michigan 49503, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • Saginaw Valley Medical Research Group
    Saginaw, Michigan 48604, United States
  • Radiant Research (St. Louis)
    Saint Louis, Missouri 63141, United States
  • Billings Clinical Research
    Billings, Montana 59101, United States
  • Montana Health
    Billings, Montana 59102, United States
  • Women's Clinic of Lincoln
    Lincoln, Nebraska 68510, United States
  • Affiliated Clinical Research INC
    Las Vegas, Nevada 89113, United States
  • Affiliated Clinical Research
    Las Vegas, Nevada 89128, United States
  • Lawrence OB-GYN Clinical Research
    Lawrenceville, New Jersey 08648, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Bosque Women's Care
    Albuquerque, New Mexico 87109, United States
  • Southwest Clinical Research
    Albuquerque, New Mexico 87109, United States
  • Columbia University
    New York, New York 10032, United States
  • Suffolk OB/GYN
    Port Jefferson, New York 11777, United States
  • Upstate Clinical Research Associates
    Williamsville, New York 14221, United States
  • Women's Wellness Clinic
    Durham, North Carolina 27713, United States
  • Carolina Medical Trials
    High Point, North Carolina 27262, United States
  • Centre OBGYN
    Raleigh, North Carolina 27607, United States
  • Wake County Research
    Raleigh, North Carolina 27612, United States
  • Lyndhurst Clinical Research
    Salem, North Carolina 27103, United States
  • Carolina Medical Trials
    Winston-Salem, North Carolina 27103, United States
  • Hawthorne Research
    Winston-Salem, North Carolina 27103, United States
  • Triad Ob-Gyn
    Winston-Salem, North Carolina 27103, United States
  • Lillestol Research
    Fargo, North Dakota 58103, United States
  • Radiant Research (Akron)
    Akron, Ohio 44311, United States
  • University of Cincinnati Physicians Company
    Cincinnati, Ohio 45267-0457, United States
  • Rapid Medical Research
    Cleveland, Ohio 44122, United States
  • Columbus Center for Women's Health Research
    Columbus, Ohio 43213, United States
  • HWC Women's Research Center
    Englewood, Ohio 45322, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Sunstone Medical Research
    Medford, Oregon 97504, United States
  • The Clinical Trial Center
    Jenkintown, Pennsylvania 19046, United States
  • Clinical Research of Philadelphia
    Philadelphia, Pennsylvania 19114, United States
  • Clinical Trials Research Services, LLC
    Pittsburgh, Pennsylvania 15206, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Fellows Research Group
    Bluffton, South Carolina 29910, United States
  • Vista Clinical Research
    Columbia, South Carolina 29201, United States
  • Upstate Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Chattanooga Medical Research
    Chattanooga, Tennessee 37404, United States
  • Volunteer Research Group/NOCCR
    Knoxville, Tennessee 37920, United States
  • DiscoveResearch, Inc.
    Bryan, Texas 77802, United States
  • Advanced Research Associates
    Corpus Christi, Texas 78414, United States
  • Research Across America
    Dallas, Texas 75234, United States

Showing the first 100 of 119 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, Guyatt GH, Norton PG, Dunn E. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996 Jul;24(3):161-75. doi: 10.1016/s0378-5122(96)82006-8. Erratum In: Maturitas 1996 Nov;25(3):231. PubMed 8844630 ↗
  • Gerlinger C, Gude K, Hiemeyer F, Schmelter T, Schafers M. An empirically validated responder definition for the reduction of moderate to severe hot flushes in postmenopausal women. Menopause. 2012 Jul;19(7):799-803. doi: 10.1097/gme.0b013e31823de8ba. PubMed 22228322 ↗
  • Spritzer, K. L. & Hays, R. D. (2003, November). MOS Sleep Scale: A Manual for Use and Scoring, Version 1.0. Los Angeles, CA.
  • Kurman RJ, Ellenson L H, and Ronnett B.M., ed. Blaustein's Pathology of the Female Genital Tract. 6th ed. New York, NY: Springer; 2011:305-452.
  • Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008 Feb;61(2):102-9. doi: 10.1016/j.jclinepi.2007.03.012. Epub 2007 Aug 3. PubMed 18177782 ↗
  • Hays RD and Stewart AL. Sleep measures. In AL Stewart & JE Ware (eds), Measuring functioning and well-being: The Medical Outcomes Study approach (pp 235-259). Durham, NC: Duke University Press, 1992.
  • McClung MR, Kagan R, Graham S, Bernick B, Mirkin S, Constantine G. Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms. Menopause. 2022 Feb 14;29(3):304-308. doi: 10.1097/GME.0000000000001915. PubMed 35213517 ↗
  • Constantine GD, Simon JA, Kaunitz AM, Pickar JH, Revicki DA, Graham S, Bernick B, Mirkin S. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial. Menopause. 2020 Nov;27(11):1236-1241. doi: 10.1097/GME.0000000000001602. PubMed 33110039 ↗
  • Black DR, Minkin MJ, Graham S, Bernick B, Mirkin S. Effects of combined 17beta-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial. Menopause. 2020 Sep 14;28(1):32-39. doi: 10.1097/GME.0000000000001659. PubMed 32932401 ↗
  • Kaunitz AM, Bitner D, Constantine GD, Bernick B, Graham S, Mirkin S. 17beta-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial. Menopause. 2020 Dec;27(12):1382-1387. doi: 10.1097/GME.0000000000001615. PubMed 32740481 ↗
  • Mirkin S, Goldstein SR, Archer DF, Pickar JH, Graham S, Bernick B. Endometrial safety and bleeding profile of a 17beta-estradiol/progesterone oral softgel capsule (TX-001HR). Menopause. 2020 Apr;27(4):410-417. doi: 10.1097/GME.0000000000001480. PubMed 31913228 ↗
  • Lobo RA, Kaunitz AM, Santoro N, Bernick B, Graham S, Mirkin S. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. Climacteric. 2019 Dec;22(6):610-616. doi: 10.1080/13697137.2019.1640197. Epub 2019 Jul 31. PubMed 31364889 ↗
  • Mirkin S, Graham S, Revicki DA, Bender RH, Bernick B, Constantine GD. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17beta-estradiol/progesterone. Menopause. 2019 Jan 9;26(6):637-642. doi: 10.1097/GME.0000000000001294. PubMed 30601452 ↗
  • Kagan R, Constantine G, Kaunitz AM, Bernick B, Mirkin S. Improvement in sleep outcomes with a 17beta-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women. Menopause. 2018 Dec 21;26(6):622-628. doi: 10.1097/GME.0000000000001278. PubMed 30586005 ↗
  • Lobo RA, Archer DF, Kagan R, Kaunitz AM, Constantine GD, Pickar JH, Graham S, Bernick B, Mirkin S. A 17beta-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. Obstet Gynecol. 2018 Jul;132(1):161-170. doi: 10.1097/AOG.0000000000002645. Erratum In: Obstet Gynecol. 2018 Sep;132(3):786. doi: 10.1097/AOG.0000000000002859. PubMed 29889748 ↗
  • Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF. 17beta-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. Maturitas. 2015 May;81(1):28-35. doi: 10.1016/j.maturitas.2015.02.266. Epub 2015 Mar 9. PubMed 25835751 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2013 to primary completion in Oct 2016, 38 months.

Results were first posted in May 2019, 2 years 6 months after primary completion. A results delay was requested in Feb 2017.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2013
First posted
Sep 16, 2013
StartActual
Aug 5, 2013
Primary completionActual
Oct 28, 2016
CompletionActual
Oct 28, 2016
Results delay requested
Feb 8, 2017
Results first posted
May 6, 2019
Last update
May 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01942668
Lead sponsor
TherapeuticsMD
Responsible party
Sponsor
First posted
Sep 16, 2013
Start date
Aug 5, 2013
Primary completion
Oct 28, 2016
Completion
Oct 28, 2016
Results posted
May 6, 2019
Last update
May 6, 2019

Study contacts

Sebastian Mirkin, MD
study director · TherapeuticsMD

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Progesterone

Start the discussion